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Abstract 
 
The aim of the thesis was to asses whether global strategies to introduce new vaccines result 
in new practices at country level and to find out whether implementation of the new vaccine 
requires changes in the existing immunization programme in Malawi. Malawi‟s decision 
making process leading to the application for support GAVI is seen as an important part of 
these objectives. The participation of the actors and their relative influence, the information 
flow including access to data on long and short term costs and benefits, and the main topics 
for discussion for the actors taking part in the process, were at the outset central topics in 
order to answer the main objectives illustrated above, with the use of semi-structured 
interviews, and available documents as a research method. Malawi is one of the poorest 
countries in the world, with high HIV/AIDS prevalence and a substantial amount of the 
population being undernourished. They started their EPI programme in 1976, and they 
introduced Hep B and Hib in 2002. The EPI programme now contains measles, DPT, HepB, 
Hib, polio, and BCG. According to the Financial Sustainability Plan from Malawi from 2004, 
the total programme cost increased significantly by over 200%, the initiation of the GAVI 
support (including the measles campaign carried out that year). An article reviewing hospital 
surveillance data for acute bacterial meningitis from Blantyre district, published in 2006, 
concludes that there is an urgent future need now for a sustainable routine infant 
immunization programme including a less expensive vaccine and new financing strategies. 
Despite the meager resources, the Malawian Ministry of Health has, according to this report, 
recognized the importance of infant Hib immunization and applied for bridge funding from 
the Vaccine Fund to allow it to continue routine infant Hib and Hep B vaccination. The 
government will during 2006 contribute to approximately 20% of the total cost of pentavalent 
vaccine. Given the tremendous number of other health priorities the country is facing it is 
unlikely that the Ministry of Health will be able to afford these costs despite the recognition 
of the vaccine benefits. This study traced the factors affecting the implementation of new 
vaccines and the effect of the introduction on the existing immunization programme. Like 
environmental problems, many health problems are international, their causes and 
consequences cross political borders. This is evident when it comes to infectious diseases, and 
in order to lift focus, and set the results in a greater perspective, the analytical framework of 
regime studies was applied. The study indicates that the decision to introduce the new 
vaccines was not based on cost-effective data and data on disease burden, but rather on the 
fact that Malawi was eligible for support, and the vaccine was available for free. The 
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introduction of SWAp seems to influence the policy context to a larger degree than the 
introduction of GAVI, as the donor community and the UN agencies already had a substantial 
funding responsibility in the health sector also before the introduction of the new vaccines. A 
somewhat unexpected finding was that the discussions concerning the new vaccines are still 
going on, and the challenge of the financial sustainability and the remaining high price of the 






























Vaccine introduction at country level; a case study in Malawi 
 
Ellen Eie 6 
1 Introduction 
 
The topic for this master thesis became an interest for several reasons. In the Bachelor degree 
in Development studies, the topic of globalisation, trade agreements, and the need for 
developing countries to create a “development space” in order to become a part in the 
international trade on their own premises, and to get the space to find and define their own 
needs, were presented. During the first semester in Master of Philosophy of International 
Community Health, lecturers representing the Global Alliance for Vaccine and Immunization 
(GAVI) gave us interesting knowledge of the concept of public private partnerships, and new 
efforts to provide the children of the world with equal access to vaccination. In an effort to 
find a research topic in this field, Professor Gunnar Bjune acted as an intermediate in getting 
in contact with Kristin Ingstad Sandberg, who was completing her PhD study on GAVI`s 
effort to speed introduction of new vaccines. The PhD study focused on the positions and 
behaviour of global actors. Kristin Ingstad Sandberg is also a research coordinator in what is 
referred to as the SUM-MEDIC project which started spring of 2008, where the 
implementation of strategies to introduce new vaccines and the capacities of national health 
system will be explored further (1). This case study will be a pilot study for a part of the 
SUM-MEDIC research project. 
 
Very often the introduction and expanding use of vaccines follow a typical pattern. They are 
first introduced in the private marked in industrialized countries, with low quantities and high 
prices. As quantities grow, they are introduced to the public marked integrated into the public 
health policies of industrialized markets, with a lower price to the public market than to the 
private market. At this time the vaccine is also introduced to the private markets of the 
developing countries at intermediate prices, which partly compensates for the loss of 
customers who previously were a part of the private market of the industrialized countries. 
Finally, the vaccine becomes used in general, with massive purchases at low prices in the 
public markets of developing countries, directly or through international procurement 
agencies such as for example the United Nations Children‟s Fund (UNICEF) (2). The 
vaccines must be introduced into the different countries on the countries‟ own premises, and 
adjusted according to the countries‟ own vaccination programmes. With the new public 
private partnerships like GAVI, the financing part is supposed to be eased, although this 
might just be solved on a short term basis. From the PhD study it was shown that even though 
the financial bottleneck was solved, there were still problems in getting new vaccines into 
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low-income countries. The study indicated two diverging positions among GAVI partner 
agencies on new vaccine introduction. One argument was that many country level 
immunization programmes are too weak to absorb new antigens, and on the other hand the 
argument was that introduction of new vaccines through combination vaccines does not place 
additional stress on the health system (1). This is a case study that aims to get an 
understanding of what influenced the government‟s decision making process in the 
introduction and adoption of new vaccines in Malawi. The focus for this study is the 
Haemophilus Influenzae B and Hepatitis B vaccines which Malawi introduced with GAVI 
support in 2002. The study focuses primarily on the decision making process during the years 
1998-2002 concerning the adoption of the vaccines to the national immunization programme, 
but also includes the discussions on financial sustainability that followed until 2005.  
 
The main objectives of the study are developed in accordance with the objectives for the 
SUM-MEDIC research project (Appendix 9). This project has as an ambition to study vaccine 
demand and coverage at different levels; from the global to the national and local levels. The 
part that this study relates to, concerns the interface between the global and national level, 
studied through processes of new vaccine implementation. Like environmental problems, 
many health problems are international, their causes or consequences cross political borders. 
To combat these problems requires coordination among states. When widely accepted 
principles and norms govern behaviour, it can be called an institution or a regime. Like in 
international environmental commitments there are many factors influencing the international 
health commitments as well. Therefore research aiming at tracing cause and effect can be 
difficult (3). As an analytical framework, however, regime studies lift focus from the 
programmatic and technical capacities at country level, to its interface with the global 
enabling environment (4). The analytical approach is adapted from environmental regime 
studies, and this adaptation demands a certain adjustment and justification of objectives. The 
different concepts used in the objectives will be clarified further in section 3.3 concerning the 
analytical framework and study design. 
 
From the outset, the research question for the case study was twofold; Do global strategies to 
introduce new vaccines result in new practices at country level?; Does implementation of the 
new vaccine require changes in the existing immunization programme? 
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From regime implementation studies, the main research issues that follow are:  
 To identify political and institutional factors that affect implementation of new 
vaccines 
 To study the role of international norms on new vaccine introduction in national 
decision-making processes 
 To study whether problem solving capacities of countries and international partner 
agencies can explain performance on new vaccine introduction  
 To trace the actual decision-making processes, taking into account the following 
explanatory factors:  
o The actors‟ relative influence in the process 
o Facilitation of adequate information flows 
o Access to data on long and short term costs and benefits 
o Toleration of dissent 
 
The method used to obtain the results is qualitative in depth interviews and review of 
documentation from meetings during the time of discussion. Documents from Malawi 
Ministry of Health (MoH), Global Alliance for Vaccine and Immunization (GAVI), 
University of Malawi, and others are also part of the data. 
 
In the following chapters, chapter 2 will aim at giving the reader some background knowledge 
and will give a short presentation of some of the already existing literature concerning this 
topic, together with information of the major stakeholders in immunization, including 
information concerning Malawi. Chapter 3 will give a presentation of the methodology and 
theoretical framework used to obtain the results, together with the study design. In chapter 4 
the results of the case study will be presented and in chapter 5 the results will be discussed 
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2 Background 
 
This case study covers many aspects which could need an extensive description and 
discussion on their own, something the limited size of this thesis will not allow. Instead, some 
short clarifications will be made of the main concepts this case study is concerned with, and 
how they are used in relation to this topic. In order to get the necessary background 
knowledge this chapter will give a short presentation on some of the already existing literature 
concerning this topic. 
 
2.1 The process of new vaccine introduction  
 
Published literature concerning the decision making process at country level is scarce. 
However, some articles suggested to be relating to this topic will be presented in the 
following. There is also so-called grey literature
1
, concerning this and relating topics, some 
will be included in the following presentation while just giving the information of the 
existence of others.  
 
An article concerning the introduction of the Hep B vaccine in Taiwan and Thailand, gives 
some interesting knowledge concerning what influences government adoption of vaccines in 
developing countries. The countries concerned are both considered as middle income 
countries, and they were some of the first countries to adopt the vaccine, several years after it 
became available in 1984, but before the WHO‟s endorsement in 1992. This article suggests 
that vaccine cost and political will is given as the two most often cited considerations when it 
comes to introducing new vaccines, but shows that although price was a critical constraint in 
Thailand, it was not so in the case of Taiwan, to a degree which is not explained simply with 
reference to its higher income. Disease burden, programmatic feasibility, proactive role of the 
medical association combined with an already strong EPI programme were all common 
supporting factors for the two countries. The differences were, in addition to the sensitivity to 
price, the international support, being critical to Thailand and entirely absent in Taiwan. The 
potential for local manufacturing was important for the decision making in Taiwan, but only 
played an indirect role in Thailand. The article underlines the importance for both countries of 
the policy making environments that were in part open to multiple inputs and actors and at 
                                                 
1
 Grey literature or grey papers is in this case study literature written for Universities or Organizations, only 
published in their own organization or on the internet 
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least partly evidence based. This is far from typical, particularly in the developing world, due 
to “weakly institutionalized processes of policy making as well as power and resource 
asymmetries between donors bringing much needed finance, on the one hand, and country 
health and finance ministries on the other” (2, page 12). The article underlines the need for 
further studies on the policy process concerning the adoption of new vaccines (2).Their 
analysis of the policy process is also particularly interesting because the introduction 
processes studied took place before the development of GAVI. 
 
Another article, published in 1999, is concerning the experience of introducing the Hib 
conjugate vaccine in the non-industrialized world. The decision-making process, the mode of 
introduction, the effectiveness, and the impact on the immunization programme of the vaccine 
were evaluated for the countries of Qatar, Uruguay, Chile and Kuwait. The countries had 
introduced the vaccines quite recently, the first country in 1993, and the last one in 1997. The 
article outlines the decision making process as the area where it was most difficult to obtain 
objective information. The results from the study indicated, however, that the introduction of 
the vaccine was initiated by the Ministry of Health (MOH), with the scientifically accepted 
disease burden data being a key factor together with the severity of the disease. The major 
concern to be dealt with in the decision making process was, for three of the four countries, 
the price of the vaccine. Although the cost of the vaccine has declined gradually and 
continues to do so, according to this article, it remains the single largest obstacle to wider use 
in most of the world. The authors recommend further studies especially concerning the 
process leading to the decision to adopt a new vaccine (5).  
 
In an article concerning policy analysis a defined framework for the introduction of vaccines 
in developing countries is given. This framework lays out five essential overlapping and 
complementary elements of successful introduction of vaccines in developing countries. 
These elements are measurement of disease burden and computation of vaccination cost-
effectiveness, conduct of large-scale vaccine introduction trials, establishment of international 
and national consensus on need for the vaccine along with recommended practices for use, the 
assurance of adequate and competitive supply and the creation and sustenance of funding 
mechanisms for procurement of the vaccine. It gives the case of the introduction of Hep B 
vaccine in Indonesia as an example. The policy analysis was conducted to support a model 
immunization programme on the island of Lombok. The issues were anticipated and dealt 
with systematically and in advance rather than addressed reactively as they arose. The article 
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outlines the need for further research on policy analysis in order to enhance health in 
developing countries (6). 
 
The limitations of sustainable introduction of affordable new vaccines have been the 
governments‟ inability to finance the vaccines due to several factors, according to an article 
by Amie Batson, published in 1998. These factors include dependency on donors, donor 
policy, and inadequate recognition by governments of the value of the vaccine, and, for some 
countries, the absolute price of the vaccine. Taking the example of the Hep B vaccine, this 
article suggests that it is the economics and not epidemiology which dictates introduction of 
the vaccine into national immunization programmes. The article outlines a framework 
developed and adopted by WHO and UNICEF, to evaluate a country‟s capacity to be 
financially self-sufficient in immunization, using relative wealth of the population, total 
market size, and total population. The details will not be presented further here, but based on 
this framework, the article suggests price elasticity, or tiered pricing of vaccines, which means 
different prices for different markets based on each market‟s capacity to afford the vaccine. 
As donors has expressed grave concerns about the financial feasibility of introducing new 
vaccines, the segmented markets with appropriate tiered prices could provide a possibility for 
handing off the financial responsibility of immunization programmes to governments, and to 
enable all countries to have rapid access to new vaccines (7).  
 
A paper published by Save the Children, describing the country level experiences of applying 
for support from GAVI in Tanzania, Mozambique, Ghana and Lesotho, GAVI was generally 
seen as a positive development in all four countries as it renewed focus on EPI where the 
vaccine preventable diseases had dropped down the priority list. However, all four countries 
experienced pressure to make rapid decisions and in some cases were subject to unreasonably 
tight deadlines in the application process. The new initiative also had to fit alongside pre-
existing commitments and priorities, and the MoH staff was not able to make immediate 
changes to systems at the delivery level, such as reporting systems, retraining staff and new 
record cards. In the countries included in this study the Inter-Agency Coordinating Committee 
(ICC) was dominated by donor and MoH staff whose main interest was in EPI. They focused 
on GAVI criteria and were less concerned about how GAVI would fit into wider programmes 
of work within SWAp processes. Bilateral donors expressed concern that GAVI was re-
verticalising donor support to health, and that it was overextending limited capacity, among 
other things. Other findings from this study were that the likely impact of GAVI will be 
Vaccine introduction at country level; a case study in Malawi 
 
Ellen Eie 12 
highly dependent on the capacity and performance of the current health systems. In Ghana 
and Mozambique where district level assessments were conducted, they had major difficulties 
in recording and reporting valid and reliable data on immunization coverage. As increased 
coverage is one of GAVI`s targets, there is a risk that this places excess emphasis on reporting 
and monitoring of quantitative data, which could be manipulated so as to increase rewards. 
The report questions the reward systems for global health, which is also an argument in 
Hardon and Blume‟s article presented later in this study, including the argument that there is a 
risk with this system that funds are used to raise the overall coverage rather than to address 
some of the inequities within the country. A notable finding in this study is the apparent lack 
of discussion and co-ordination around future financing, involving major donors at the 
country level. The arguments put forward is that the different Ministries of Health have been 
dependent on external support for a long time and therefore remain pragmatic in anticipating 
that funds will eventually follow the plans and priorities of the sector. As donor commitments 
are usually set for one or maybe two years, it is understandable that they welcome a five year 
commitment. The cost of sustaining such commitments after the five years becomes a 
challenge to the health sector and to the international community as there seems to be an 
assumption by the Ministries of Health that the costs will be picked up by donors or 
international organisations (8). 
 
In an article on Immunization in Developing Countries, Gauri and Khaleghian try to explain 
why some countries have stronger immunization programmes than others using the vaccine 
coverage of DPT and measles together with the adoption of the Hep B vaccine as a measure. 
The explanation they find is that broad changes in the global policy environment and contact 
with international agencies, together with the quality of a nation‟s institution and its level of 
development, are strongly related to immunization coverage and vaccine adoption in low 
income countries. It also shows that national coverage rates are more a function of supply-
side than the demand effects. The paper outlines the importance of the exchange of 
professional knowledge, autonomy for public health managers, the quality of national 
institutions, and the involvement of international agencies in raising immunization coverage 
rates. In order to increase the effect on the demand side the paper suggests larger and more 
sustained efforts to motivate people to get vaccinated (9).  
 
Further studies belonging to the area of grey literature is an unpublished policy study on 
factors influencing the adoption of new and underutilized vaccines in developing countries, 
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by Brooks, Cutts and Walt(10), together with a study concerning the same topic done in 
Bangladesh, Phillipines and Uganda by Judtith Justice (11), and a study on the introduction 
and use of new vaccines in the public and private sectors, using Morocco, Thailand and 
Zimbabwe (12) as examples. These will not be described further due to the limit of the size of 
the thesis, but only mention their existence if further reading should be desired.  
 
2.2 Haemophilus Influenzae B, Hepatitis B and vaccine cost-
effectiveness 
 
This is not a case study on the diseases caused by Hepatitis B and Haemophilus influenzae 
type B, or on technical aspects of the vaccines which could prevent them. The medical details 
on the anatomy physiology of the diseases they cause, the treatment, or how they are 
prevented by the vaccine will therefore not be explored here. Instead, this is a case study 
concerned with the political discussions and the decision making process which took place 
prior to the introduction of the vaccine. In order to get a broader understanding of the topic 
however, there will be short clarifications of the two vaccines and the diseases they cause. 
 
Haemophilus influenzae type B (Hib) 
Hib is a bacterium estimated to be responsible for some three million serious illnesses and an 
estimated 386,000 deaths per year. It is commonly found in the noses and throats of healthy 
individuals and is spread by exhaled droplets. From there it can invade the bloodstream and 
cause infection and disease in other parts of the body. Most commonly it causes meningitis 
and pneumonia mainly in children under the age of five and more rarely septic arthritis (an 
inflammation of the joints), septicemia (blood poisoning) and epiglottitis (swelling of the 
epiglottis; piece of cartilage at the back of the tongue that closes off the windpipe when 
swallowing). But- these diseases can also have other causes.  In developing countries 
pneumonia accounts for a larger number of deaths than meningitis, although Hib meningitis 
have mortality rates several times higher than is seen in developed countries and leaves 15 to 
35 % of those who survive with permanent disabilities  such as mental retardation or deafness. 
The vaccine has been available since the 1990‟s. However, the Hib disease is difficult to 
diagnose, and the price is seven times the cost of the original DPT vaccine. WHO therefore, 
recommends it “where resources permit its use and the burden of disease is established”. This 
was from the position paper from WHO in 1998 (13). There is a new position paper from 
WHO from 2006, however, that advocates clearly the desirability of Hib use in all countries 
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(14). The testing of Hib from blood specimen (pneumonia) or spinal-fluid specimen 
(meningitis) needs sophisticated laboratories, and the disease may still be masked because 
antibiotics were given before the samples were taken (15). 
 
Hepatitis B (Hep B) 
Hepatitis means inflation of the liver, and the most common cause is infection with one of 
five viruses, called hepatitis A, B, C, D, and E. All of them can cause acute diseases, but Hep 
B is the most serious type of viral hepatitis and the only type causing chronic hepatitis. In 
most of the developing world (including sub-Saharan Africa) most people become infected 
with Hep B during childhood, and 8% to 10% of people in the general population become 
chronically infected. About 90% of infants infected during the first year of life and 30% to 
50% of children infected between 1 to 4 years of age develop chronic infection. The risk of 
death from Hep B related liver cancer or cirrhosis is approximately 25% for persons who 
become chronically infected during childhood. The Hep B virus is transmitted by contact with 
blood or body fluids, and is 50 to 100 times more infectious than human immunodeficiency 
virus (HIV). The most common ways of getting infected with Hep B are from mother to baby 
at birth (perinatal), child-to-child transmission, unsafe injections and transfusions and through 
sexual contact. WHO recommended all countries to add Hep B vaccine into their national 
immunization programmes in 1991(16). 
 
Cost-effectiveness 
In a statement from the World Bank in connection with the first introductions of vaccines at 
the very beginning of GAVI, the president of the World Bank at the time, Mr. James 
Wolfenshon states that “Immunization is one of the most cost-effective health 
interventions….we know immunization to be a sound investment…….The link between 
health and wealth is a strong one" (17). Cost effectiveness is a central concept when talking 
about immunization, and its definitions and calculations could be discussed extensively. Due 
to the limitations of this thesis, this will not be done here. Some definitions of the concept will 
be given however, and a clarification of how it is meant to be used in this case study.  
According to WHO; “Immunization is undoubtedly one of the most cost-effective health 
achievements of modern times. It protects against the long-term effects of a disease on a 
person‟s physical and mental well-being and thereby the ability to complete education or 
training and carry out work. This protection entails un-measurable individual and societal 
benefits in terms of earning capacity, productivity and growth. In other words, immunization 
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prevents death and disability at a fraction of the cost of treatment, to the benefit of both the 
individual and the society as a whole. Effective health policies and related expenditure must 
be seen as an investment, not a cost. Good health boosts economies while illness drains them” 
(18).  A review article concerning the economic aspects of vaccines and immunization, 
indicates that in the 162 articles carried out on economic evaluations of vaccines from 1969-
1998, consistently show that immunization is an excellent investment, highly cost-effective, 
and usually cost-saving for vaccines that are currently recommended for universal use (19). 
The article is published in 1999, but takes into considerations that although prices of newer 
vaccines are higher than prices of traditional vaccines, they are still highly cost-effective. It 
also elaborates on the issues of cost-benefit and cost-effectiveness. When seeking to evaluate 
if immunization is worthwhile, several techniques are used. Cost-benefit analysis requires 
assigning a monetary value to all costs and all benefits of a policy or programme. The benefits 
are calculated by estimating the total cost of disease in the absence of intervention and 
subtracting the total costs of residual disease occurring with the programme. The cost of the 
programme include vaccines, vaccine administration, costs of dealing with adverse events and 
other programme costs such as public education. Benefits and costs can be direct (e.g. cost of 
medical care or indirect (e.g. time off from work to care for a sick chid). If the benefit divided 
by cost ratio is greater than 1.0, the intervention is considered to be cost saving. In cost-
effectiveness analysis, the question is how much it costs to achieve a particular outcome, and 
no attempt is made to assign a value to the life or illness. Interventions are considered cost-
effective if the cost per year of life saved is less than, or equal to, the per capita gross 
domestic product. It is particularly useful when comparing several strategies to achieve a 
single effect.  A specific form of Cost-effective analysis is cost-utility analysis, where 
outcomes are reduced to a common denominator such as the quality-adjusted life year 
(QALY) or disability adjusted life year (DALY). This makes it possible to compare problems 
with different outcomes, such as illness and death versus prolonged disability. The definitions 
used in this article will also be used in this case study. There are striking differences between 
the UNICEF prices for traditional vaccines and the prices of the newer ones. In general, the 
newer generations of vaccines are much more complicated and expensive to develop and 
produce and are protected by intellectual property rights. In addition, research and 
development costs have not yet been recouped and with the development of the biotechnology 
more and more possible avenues for research and development are opening. Both the hepatitis 
B and Hib vaccine are highly cost-effective in developing and developed countries, according 
to this article, but the question is whether they can be afforded (19). Cost-effectiveness is thus 
Vaccine introduction at country level; a case study in Malawi 
 
Ellen Eie 16 
used both as a political argument about the value of vaccines, and as a tool to calculate if the 
adoption of a new vaccine into a national immunization programme is justified from an 
economic and public health perspective. In the latter case, the calculations depend on 
information about disease burden and projected vaccine prices. Good information on these 
two factors was one of the challenges facing GAVI when it started vaccine-introduction 
processes in 2000 (19). 
 
2.3 The role of GAVI in relation to new vaccine introduction 
 
GAVI was created in 1999 to give greater access to the benefits of immunization. It is an 
Alliance of public and private resources, consisting of research institutes, pharmaceutical 
industry, non-governmental organisations, donor-and recipient countries, the Gates 
foundations, UNICEF, WHO, and the World Bank. One of the main goals of GAVI is solving 
the problem of delays in introduction of new vaccines to low-income countries, but also to 
strengthen the existing immunization systems. Prior to GAVI, new vaccines took on average 
15-20 years before they reached the children in the developing world, and this gap threatened 
to grow, as more new vaccines were about to be introduced in the marked. An expansion of 
the marked for new vaccines could stimulate manufacturers‟ further investments in products 
for low income countries, and also contribute to bring down the prices of the vaccines.  The 
GAVI partner agencies took on different areas of responsibility towards new vaccine 
introduction, according to their comparative advantage (4). GAVI is not a UN-led initiative. It 
is governed by a board of 16 (also given as 15 in other literature, depending on if the Vaccine 
Fund is included as a member of the board) institutional members, including 5 (this number is 
also given as 4 in other literature) permanent members and 11 rotating ones. The permanent 
seats are occupied by the Bill and Melinda Gates Foundation, the Vaccines Fund (not 
mentioned as a member in other literature), WHO, UNICEF and the World Bank. The 11 
rotating seats represents developing countries (2 seats), developed countries (3 seats), NGOs 
(1 seat), developing country industry (1 seat), developed country industry (1 seat), 
foundations (1 seat), technical health institutes (1seat), and research and academia (1 seat). 
Creating an independent secretariat outside the UN meant to avoid delays in plan 
implementation associated with UN bureaucracies. The emphasis on the introduction of new 
vaccines made the industry willing to participate in the GAVI Alliance. The conditions for the 
industry participation were outlined at the first GAVI Partners meeting in the Netherlands in 
2000. The conditions included a guarantee for „reasonable prices‟, support for a credible and 
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sustainable market, respect for international property rights, a tiered pricing system including 
safeguards against re-export of products back from developing countries to high-priced 
markets and a prohibition on compulsory licensing ( a legal option included in the 
international trade agreement on intellectual property rights (TRIPs), granting a licence to a 
third party without the consent of the patent holder, issued on various grounds including 
public health, giving the patent holder a compensation) (20).   
 
According to a GAVI commissioned evaluation of the Accelerated Development and 
Introduction Plan (ADIPs), GAVI had no coherent vaccine supply strategy in 2002, where the 
supplies of the preferred vaccines for delivering the Hep B and the Hib antigens in the 
tetravalent and the pentavalent combination were severely limited with only one manufacturer 
for both of them. UNICEF Supply Division was procuring vaccines pre qualified by WHO. 
The supply constraint was exacerbated by delays at country level with placing orders and 
setting up introduction plans which led to a mutual distrust between the multinational 
manufacturers and GAVI.  Increasing the industrial capacity for the GAVI market seemed 
therefore an unlikely possibility at the time. This created further a market imbalance; where 
UNICEF as the only buyer was working to obtain the lowest possible prices for countries, 
while the one seller in the absence of competition, saw no need to lower prices (14). The 
intention in GAVI, one global partner representative said, was that the different members of 
the Alliance should concentrate on what was their comparative advantage. WHO had a 
normative (determining norms or standards) function while for example UNICEF had more of 
the logistics and vaccine purchase and distribution; the World Bank took care of the funding 
and so on (i7.GPR). 
 
2.3.1 The introduction strategy   
In GAVI phase 1
2
(2000-2005), the strategy for introduction of new and under used vaccines 
was to provide the vaccines for free for the first five years of support, without demanding any 
co financing from the recipient countries. After the five years, the marked forces were 
expected to drive the prices down in the marked, enabling countries, and the donor 
community to be able to incorporate the vaccine costs in their own health budgets (4).   
During these first five years the Alliance has committed over 1.2 billion dollars (the numbers 
                                                 
2
 GAVI phase 1; The term used to describe GAVI policies and priorities during its initial 2000-2005 period 
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vary in the literature, up to 1.5-1.6 billion US$) and disbursed over 480 million US$ to 71 of 
the 75 eligible countries.  





Only countries with an annual GNI/capita below $1000 are eligible, and immunization 
services support (ISS) is provided to strengthen immunization and health systems based on 
the immunization coverage. With reported immunization coverage above 80%, the country is 
not eligible for ISS support (22). The three basic conditions for support for eligible countries, 
adopted by the GAVI Board October 4
th
 2000 were in phase 1:  
1. A functioning Inter-agency Coordination Committee or equivalent collaboration 
mechanism 
2. A recent assessment of immunization services 
3. A multi-year plan for immunization  
In addition countries are expected to follow safe immunization procedures and have plans to 
improve safety if there is room for improvement (23).   
 
Inter-agency coordination committee (ICC) 
According to GAVI the Inter-Agency Coordinating Committee (ICC) is a key coordinating 
mechanism for immunization services in developing countries. They are usually chaired by 
the Ministry of Health. Members of the committee include development partners such as the 
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World Health Organization, UNICEF, nongovernmental organizations, and donor 
governments (24).  
At each step of the application and monitoring processes pictured above, GAVI requests 
countries to submit a number of forms and documents. 
These include: 
Annual progress report 
One of the conditions for continued support from GAVI is an annual progress report. All 
countries receiving support from GAVI must submit annual progress report to the monitoring 
team of the Independent Review Committee. This committee assesses the report and provides 
recommendations for approval to the GAVI board (24). 
Financial Sustainability Plan 
The Financial Sustainability Plan (FSP) describes the governments approach to mobilise and 
use resources to support medium and long term immunization objectives. The countries were 
requested to submit their FSP to GAVI at the mid point in their period of support during the 
first phase of GAVI. The FSP is now integrated into the comprehensive Multi Year Plan 
required for every application for support (24). 
Multi Year Comprehensive Plan 
The comprehensive multi-year plan for immunization (cMYP) is a is a key planning and 
management tool for national immunization programmes which  addresses global, national, 
and sub national immunization objectives and strategies, and evaluates the costs and financing 
of the programme. This is now in line with the WHO-UNICEF Global Immunization Vision 
and Strategy (GIVS) 2006-2015. A cMYP is required along with the standard proposal form 
when applying for GAVI support. The cMYP replaces the Financial Sustainability Plan” (24). 
 
Bridge financing 
The GAVI Board has agreed to provide so-called „bridge-financing‟ to those countries which 
used GAVI resources to introduce the more expensive combination vaccines (DTPHepB, 
DTPHep-B-Hib) in Phase 1. This was worked out as a solution at the end of Phase 1, when 
recipient countries and their health aid donors were not able to take over the costs of new 
vaccines, as GAVI had planned initially. It is a concept of co-financing with the receiving 
countries and donor agencies, where the aim is for GAVI to gradually phase out. The 
feasibility of co-financing will depend upon the willingness and ability of country 
governments and other donors to contribute to vaccine costs. The exact mechanics of bridge 
financing are now being developed but they will entail extending support to those countries 
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which will gradually contribute their own resources to co-finance vaccine procurement (25).   
According to the HLSP evaluation looking at the Hib vaccine introduction picture in 2005,  it 
was recognized that since the price of the pentavalent vaccine had not gone down, and 
countries yet had to fully implement financial sustainability plans, there would be a need to 
extend the vaccine financing, and the Bridge Financing concept was introduced. For some of 
the countries that had incorporated the Hib vaccine into their immunization programme, this 
decision was not necessarily sustainable after the financing from GAVI ran out (14).  
 
2.3.2 The role of WHO and UNICEF in relation to immunization 
The success of the eradication of smallpox, led WHO to create the Expanded Programme on 
Immunization (EPI) in 1974, and later, UNICEF to set the Universal Childhood Immunization 
goal (UCI). They were both dedicated to establishing routine immunization services in every 
country to protect children from 6 vaccine preventable diseases: diphtheria, tetanus, pertussis, 
measles, poliomyelitis and tuberculosis, and focused on creating demand and establishing the 
basic delivery infrastructure (7). UNICEF served as the leading donor in most developing 
countries and procured and supplied the projected amount of vaccines needed. WHO acted as 
a technical partner, providing most of the training materials and assistance in information 
systems, cold chain storage, disease surveillance and evaluation (20).WHO and UNICEF 
were recognized as key agencies in GAVI through their expanded programme on 
immunization (EPI), UNICEF being the vaccine procurement agency, financed through the 
Vaccine Fund, and WHO the lead agency in terms of surveillance, demand forecasts, and 
guiding countries in their selection of vaccines and vaccine presentation. This is also 
illustrated in the figure above, where WHO will give the technical support illustrated in point 
8 in the figure and UNICEF supply division being responsible for the procurement of the 
vaccine financed through the vaccine fund at point number 7 in the figure above. According 
to GAVI, WHO should also assist in disease burden studies and effectiveness trials to assess 
the importance of new vaccines at country level. The World Bank were responsible for the 
financing issues, including the financial sustainability plan, and the developing-country 
governments were responsible for the multi year immunization plan, to coordinate the 
external inputs and to assure contributions from government budgets. The advocacy for new 
vaccines was allocated to the Children‟s Vaccine Programme (CVP) (4).  
WHO and UNICEF have in cooperation produced a 10-year immunization framework: the 
Global Immunization Vision and Strategy (GIVS), for the years 2006–2015. This framework 
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aims to expand the benefits of immunization to all people so that immunization contributes to 
the Millennium Development Goals (MDGs), global security and cancer prevention. In 
addition to this WHO‟s role is to provide technical support to countries, in terms of assisting 
with the design, financing and implementation of strengthened sustainable national 
immunization programmes (26). According to WHO, on the issue of immunization, the 
organization is responsible for supporting and facilitating research and development, ensuring 
the quality and safety of vaccines, developing policies and strategies for maximizing the use 
of vaccines, reducing financial and technical barriers to the introduction of vaccines and 
technologies, and supporting countries in acquiring the skills and infrastructure needed (13). 
According to GAVI, the GAVI Alliance depends on WHO's guidance on technical issues. 
WHO, along with UNICEF, plays a key role in supporting countries in their application for 
GAVI funds, and the following implementation and monitoring of GAVI-related 




2.4.1 Country facts 
Malawi is a land locked country with Lake Malawi covering 20 % of the surface area. The 
country is divided into three regions, the Northern, the Central and the Southern region, which 
in turn are divided into 28 administrative districts. The population was projected to be 
12,757,883 in 2006 (28). The country has a low life expectancy, decreasing from 41.8 in 
1970-1975 to 39.6 in 2000-2005. The GNI/capita in US$ is 160, the GDP/capita is 667 US$ 
(GDP per capita is PPP adjusted) (29).    
 
2.4.2 Health, disease and immunization in Malawi 
An unpublished study from the University of Malawi from 1997 concerning the constraints, 
proposed improvements and sustainability of Expanded Programme on Immunization (EPI) in 
Malawi, can give important information on how the vaccination programme worked prior to 
GAVI and the introduction of the new vaccines. The study is a result of key informant 
interviews. The results from this study suggest that several factors have already disrupted or 
may threaten to disrupt the existing supply system for vaccines. These are  the over-
dependence on donors; the cash budgeting system and financial uncertainty; the unavailability 
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of vaccines at the central Vaccine Stores; logistical problems such as lack of storage, transport 
and equipment; inaccessibility of some areas due to poor road infrastructure, especially during 
the rainy season; and lack of clear and unequivocal Government commitment towards EPI. In 
order to improve and sustain the current immunization coverage rate levels, the study 
recommends the Malawi Government to have the commitment to make immunization a 
priority and take over from the donors the procurement and distribution of vaccines. The 
donor support should be solicited, and government funding assured. They also recommend 
that community participation must be strengthened, together with the operations research, the 
improvement of the IEC activities, the cold chain system, the transport and infrastructural 
system and the staffing. Another constraint mentioned by the respondents in this study was 
the lack of relevant data for decision making (30). It is reasonable to assume that the people 
interviewed in this case study are in some of the same positions as the people interviewed in 
the study mentioned above. Although the results can not be compared directly, having the 
results of this study in mind, it can indicate if there has been a change in the immunization 
programme after the introduction of GAVI and the new vaccines. 
 
Health system 
The health services in Malawi are provided by three agencies; the Ministry of Health (MOH) 
provides 60 % of service delivery, the Christian Health Association of Malawi (CHAM) 
provides 37%, and private institutions provide 3% of the health care. The health delivery 
system is divided into 4 levels; the central hospital level, the district hospital level, the health 
centre level, and the community based outreach care. All institutions provide the Expanded 
Programme on Immunization (EPI) services (28). The Ministry of Health (MOH) has created 
a cost effective package of health services, the Essential Health Package (EHP) to achieve the 
goal: “to raise the level of health status of all Malawians by reducing the incidence of illness 
and occurrence of premature deaths in the population” (31, page 10).  It focuses on vaccine 
preventable diseases, malaria, adverse maternal and neonatal outcomes including family 
planning, tuberculosis, acute respiratory infections, acute diarrhoeal disease, sexually 
transmitted infections, schistosomiasis, nutritional deficiencies, eye ear and skin infections 
and common injuries. The EHP was costed at 17.5 US$ per capita per annum in 2002. The 
health centre is the first level of contact between community health services and the formal 
health sector. Some cannot provide the EHP however, as they are only served by dispensaries 
or maternity units. At the community level the Essential Health Package (EHP) is delivered 
through Health Surveillance Assistants (HSA). Their activities include advocacy and health 
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promotion, home visits, village clinics, and meetings with communities, and the inspection of 
public facilities. The Government of Malawi has targeted a ratio of 1 HSA to every 1000 
people, but the current ratio is 1 to 2600 people. The lack of human resources in the health 
sector is substantial. Many district hospitals do not have doctors. The vacancy rate for nurses 
was 59% in public sector and 77% at CHAM facilities; the average vacancy rate for doctors at 
both facilities was 62% (28). The EPI programme was a vertical programme in the Ministry 
of Health until the discussions of sector support came along, which lead to the Sector Wide 
Approach (SWAp). The definition of a vertical programme used in this thesis, is a disease 
specific programme, planned by the central ministry and financed through earmarked funds. 
Implementation is managed through programme-specific vertical structures within the 
existing health system: drugs and other resources are usually procured through a parallel 
process; health workers are also often dedicated exclusively to programme-related activities; 
and, programme supervision and monitoring procedures are independent as well (32).  
The Sector Wide Approach (SWAp) provides a framework and environment that facilitates 
cooperating partners and government to work together for health development. The key 
strategies here are increasing the availability and retention of staff in the health sector, 
providing adequate volumes of drugs and medical supplies at all service delivery points, 
providing essential medical equipment at all health facilities, implementing infrastructure 
development, improving routine operations at the service delivery level to deliver EHP and 
other health services, and developing appropriate policies, systems, and standards to support 
central and district operations (28).    
 
Disease 
The infant mortality rate in Malawi is 76 per 1000 births and the under-five mortality rate is 
133 per 1000. Malawi is number 165 out of 177 countries on the human development index 
(33). The maternal mortality rate is one of the highest in the world at 984 deaths per 100 000 
births in 2004. Only 57% of deliveries took place in health facilities. The HIV/AIDS 
prevalence is 12 % at the age group 15-49 years (2005), and 34% of the population is 
undernourished (2001-2003) (28, 34). 
Malawi‟s major burden of disease is characterized by infectious or communicable diseases 
due to conditions such as malaria, HIV/AIDS, tuberculosis, sexually transmitted infections, 
diarrhoea and acute respiratory infections (ARI). Acute respiratory infections, diarrhea and 
malaria are major causes of childhood mortality. These conditions are worsened by the poor 
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nutritional status of children, where 49% of the children under five are estimated to be 
malnourished and stunted (28).   
 
Immunization 
The Expanded Programme on Immunization (EPI) was initiated in Malawi in 1976 as a pilot 
programme, and was fully operational in 1978. Malawi was one of the first 13 countries in 
Africa who got their proposals approved for a five-year support on the introduction of new 
vaccines from the Global Alliance on Vaccines and Immunization (GAVI). The EPI currently 
offers measles, DPT-HepB+Hib, Polio and BCG vaccines to children under 1 year of age and 
the tetanus toxoid vaccine to pregnant women and women of child bearing age. The new 





dose of DPT restarted, while those who completed the three doses of DPT were not eligible 
because they had already completed the recommended schedule for DPT (35). 
The immunization coverage in Malawi has been above 85% since 1989, except from the year 
2000 and 2002.The drop in the year 2000 can be attributed to factors such as the global 
shortage of polio, BCG and DTP vaccines due to manufacturers‟ problems (35). The drop in 
2002 might be explained by the shift in reporting system due to the introduction of the new 
vaccine (i5.CR). The DTP3, Hep B and Hib coverage was above 90% in 2005 and 2006. The 
Malawi reported coverage numbers and the WHO-UNICEF estimates correspond in these 
numbers. The immunization coverage differs among the district however, with 31% reporting 
DTP3 coverage greater or equal to 90%, 54% of the districts report the DPT3 coverage to be 
between 80-89% and 15% reporting DTP3 coverage from 50-79%. The proportion of districts 
not reporting or reporting coverage of less than 50% was zero.  In this report, the number of 
districts is given as 26, in the annual report of the work of the Malawi health sector; the 
number of districts is given as 28. Nonetheless, the numbers given says that 69 % of the 26 
districts, reported a DTP3 coverage of less than 89%, and it is therefore difficult to see that 
the overall coverage, given as reported coverage from Malawi and estimated coverage from 
WHO-UNICEF, can be 99% (28, 29). 
 
In the 2004 Malawi Demographic and Health Survey the overall number of children fully 
vaccinated by 12 months is given as 64 %. In a report from Centre for Social Research at the 
University of Malawi in the Zomba region, the number of children fully vaccinated by 12 
months of age in 2004 is given to be 51%. In some of these reports, the methods for collecting 
these numbers are given, and for some of them they are not.  The point here is to show that 
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the numbers differ according to where they are found and how they were obtained. The reader 
should have this in mind in the discussion of whether the introduction of new vaccines results 
in new practices at country level, or if it requires changes in the existing immunization 
programme (36, 37).    
 
SWAp 
Moving towards Sector-Wide Approaches (SWAp) was a stated policy decision arising from 
the May 2000 Consultative Group (CG) meetings between the government and development 
partners. The aim was to establish several joint processes in terms of planning, funding and 
procurement and monitoring and review, and they wanted to adopt a single plan of action for 
the sector as a whole to implement. A broad range of stakeholders including development 
partners and NGOs was brought onboard to implement this plan, with the overall process 
being driven by government (35). 
 
An evaluation of SWAp in several developing countries, initiated by Swedish International 
Development Cooperation Agency (SIDA), and worked out by Institute for Health Sector 
Develoment (HLSP) in 2003, have the following definitions on SWAp: 
“The sector wide approach defines a method of working between government and 
development partners, a mechanism for co-ordinating support to public expenditure 
programmes, and for improving the efficiency and effectiveness with which resources are 
used in the sector. All significant funding for the sector supports a single sector policy and 
expenditure programme, under government leadership, adopting common approaches across 
the sector and progressing towards relying on Government procedures for all funds”.  
The report has included Malawi in the countries evaluated, although Malawi was one of the 
countries in its introduction process at the time of the evaluation. The major concern for most 
countries about activities outside the SWAp were the new global initiatives, with GAVI as 
one example, in terms of the levels of funding to be received, and the management of those 
funds outside the SWAp. Malawi and Burkina Faso report that monies from global initiatives 
are expected (Malawi was due to receive huge inflows, according to this evaluation at that 
time), however that they have been taken into account in SWAp design (Malawi) and so are 
not seen as a problem for the SWAp (38). According to GAVI, the aim was for SWAp to have 
considerable efficiency and equity gains for Malawi‟s health service. Efficiency will increase 
as the transaction costs of utilizing and monitoring various sources of financial support fall, 
and joint planning ensures that duplication of service provision is minimized. Equity will 
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improve as stakeholder coordination and resource allocation become systematic. There will be 
some short-term risks to vertical service delivery structures, such as the immunization 
programme, as the SWAp develops. There will have to be a careful process of change 
management to ensure that individual MoH “success stories” (such as the EPI programme) 
are not eroded as the overall health system improves its performance (39).  
 
2.4.3 Hib and Hep B in Malawi 
There is a study done in 1996-97, before the Hib vaccine was introduced, where clinical and 
demographic data were collected on all children from the age one day to 14 years, with the 
diagnosis of bacterial meningitis (BM). The study was done in Blantyre, at Queen Elisabeth 
Central Hospital. Data was collected prospectively for one year. It was found that 2.7% (267 
out of 9847 children) of all paediatric admissions at the hospital were found to have BM, and 
of them: 83% were under 5 years of age, 61% under 1 year of age, and 23% under one month 
(= the neonatal period). Haemophilus influenzae type b (Hib) was the causative organism in 
21 % of the cases in the post neonatal period. The other causative organisms in this period 
were Streptococcus pneumoniae (27%) and Salmonella typhimurium (6%). Hib was not a 
causative organism in the neonatal cases. The overall mortality was 40%, and the outcome 
was worst in the salmonella infections particularly the neonatal salmonella BM with the case 
fatality of 89% (8 of 9 cases). Coma on presentation worsened prognosis, and 15% of the 
survivors had sequelae on discharge. One of the conclusions in the study was that vaccination 
against Hib infection would have reduced the number of meningitis cases by 16% and death 
due to the disease by 17%. It also suggests that earlier access to adequate health care and 
awareness of BM in a malaria-endemic area would reduce mortality and morbidity (40).   
 
In 2006, an article is published where cases of acute bacterial meningitis from 1984-1991 at 
Royal Liverpool Children‟s Hospital in Liverpool, UK, and from 1996-1997 at the Queen 
Elisabeth Central Hospital in Blantyre, Malawi, are compared. The results from this study 
demonstrate a marked difference. The mortality rate in Blantyre is in this article given as 41 
%, and over five times that in Liverpool with 7% mortality. Children with meningitis present 
later in Blantyre, and tend to be sicker, more anemic, more malnourished and more likely to 
be unconscious and have a history of seizures. Some of the difference in mortality is also due 
to different organisms causing meningitis, but mortality was higher in Malawian children 
even when compared with Liverpool children infected with the same organism (for example 
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Hib 43% vs 6%). Other potentially contributing factors to the higher mortality include HIV, 
malnutrition, and poorer access to medical care. Malaria can have some of the same 
symptoms as meningitis and therefore also cause a delay in hospital admittance. The article 
states that conjugate vaccines could decrease mortality from meningitis in Malawi, but gives 
no published numbers on this, but states that the data presented suggests that Hib vaccine 
could have prevented up to 25% of the cases of meningitis at the hospital and 17% of the 
deaths due to the disease (41).   
 
An article reviewing hospital surveillance data for acute bacterial meningitis in Blantyre 
district (children age 1-59 months admitted during 1997-2005), following the Hib vaccine 
introduction during 2002, show a decrease in Hib meningitis incidence rates (20-40/100 000 
to near zero) among all residents, despite no change in pneumococcal meningitis incidence 
rates. The study was a review of hospital surveillance data for acute bacterial meningitis in 
Blantyre district Queen Elisabeth Hospital, among children 1-59 months. At the time the Hib 
vaccine was introduced, WHO established the paediatric bacterial meningitis surveillance 
network (WHO PBM), and data from the WHO PBM surveillance site at Queen Elisabeth 
Central Hospital is used for this evaluation as well as historical data from the hospital 
collected before vaccine introduction. The report describes difficulties in obtaining the date 
for when vaccines were given, so the analysis was conducted from 2003 onwards when all 
children would have had the opportunity to be vaccinated (Recorded cases for earlier years 
from 1997-2002). The report states that Hib vaccine is highly effective in a country where 
health care resources are poor, and the burden of HIV is high, but because of reduced 
ambulance availability, some cases might have died before reaching the hospital, and children 
presented at the health centres were given first dose of AB, before the lumbar puncture at the 
hospital. These factors might have influenced the results of the study. Despite the meager 
resources, the Malawian Ministry of Health has, according to this report, recognized the 
importance of infant Hib immunization and applied for bridge funding from the Vaccine Fund 
to allow it to continue routine infant Hib vaccination. The government will during 2006 
contribute to approximately 20% of the total cost of pentavalent vaccine. But- by introducing 
this vaccine, together with the Hep B vaccine, in the routine immunization programme, the 
total vaccine cost per year for the government of Malawi increases from approximately 
600,000 US$ to 6,000,000 US$ per year (based on 3.3 US$ per dose), according to this 
article. Given the tremendous number of other health priorities the country is facing it is 
unlikely that the Ministry of Health will be able to afford these costs despite the recognition 
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of the Hib vaccine benefits. It concludes that thus Hib vaccine is clearly effective in reducing 
Hib meningitis; there is an urgent need for innovative financing strategies for the world‟s 
poorest countries including a less expensive vaccine that preferably is delivered in a 
multivalent form (42).  
 
An article concerning the seroprevalence of Hep B and C and HIV in Malawian pregnant 
women, published in 1998, before the introduction of the Hep B vaccine, concludes that Hep 
B and C infections are highly endemic in Shire Valley in rural Malawi. Fifty HIV-positive 
and 100 HIV-negative samples were selected randomly from 153 HIV-positive and 443 HIV-
negative women delivering in hospital. 16% of the HIV-positive mothers and 12% of the 
HIV-negative mothers were chronic carriers of Hep B. The findings showed that Hep B and C 
were highly prevalent in this rural area of Malawi and the figures obtained are in agreement 
with figures from other highly endemic areas. The exposure to the Hep B infection seemed to 
occur early in life (43).  
 
A study doing serological and molecular screening for viruses in blood donors from Ntcheu 
district, published in 2001, one year before the vaccine was introduced, shows that among 159 
blood donations 8.1% was Hep B carriers. The study also concludes that HIV-1
3
, Hep B and 
Hep C infections are highly endemic in Malawi. The numbers are lower than in the study 
mentioned above, but the study from the blood donors also states that it is generally admitted 
that screening blood donors tends to provide a lower estimate of viral marker prevalence than 
is found in the general population, as blood donors represents a younger and healthier group 
within the general population (44). A study done among male workers at a sugar estate in 
Malawi in 1998, investigated associations between HIV-1 prevalence and herpes simplex 
virus 2, hepatitis C virus, and hepatitis b virus infections, and showed among other findings, 
that the prevalence of Hep B infection was 16.9% among HIV-positive persons and 14.4% 
among control subjects who were HIV-negative, indicating high levels of acute or chronic 
Hep B infections in this population. These prevalence estimates are consistent with estimates 
reported among rural Malawian pregnant women but are slightly higher than those reported 
among Malawian blood donors. The study says further that the high prevalence of Hep B and 
Hep C are troubling because they indicate high future rates of chronic Hep B and Hep C 
complications (45).  
                                                 
3
 HIV-1 is the virus that was initially discovered and termed LAV. It is more virulent, relatively easily 
transmitted, and the cause of the majority of the infections globally 
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3 Methodology 
 
3.1 Choice of method 
 
This research is concerned with why the decision was made of implementing the new 
vaccines in Malawi, how the decision was taken, and what results the implementations of the 
new vaccines have given. The intention for this thesis is to look into the decision making 
process of Malawi in deciding to implement the new vaccines. Case studies of organizational 
decision making have long been one of the most important strategies by which researchers 
have investigated organizational behaviour and improved their theoretical understanding of 
that behaviour (46). There are many definitions of case studies. For Thomas et al. a case study 
“… is often an account and an analysis of particular events and decisions, and can be used to 
illuminate a decision or set of decisions, why they were taken, how they were implemented, 
and with what result” (47). According to Yin “(T)he essence of a case study , the central 
tendency among all types of case study, is that it tries to illuminate a decision or set of 
decisions: why they were taken, how they were implemented, and with what result” (48, page 
12). Case studies are the preferred strategy when “how” and “why” questions are being posed, 
when the investigator has little control over events and when the focus is on a contemporary 
phenomenon within some real life context. This definition, however, sites the topic of 
decisions as the major focus, and although it makes it all “fit nicely” into this research it is not 
enough to define what a case study is all about. The case study is a research strategy covering 
the logic of design, data collection techniques, and specific approaches to data analysis (48). 
Using case studies might be a challenge, however, because there are few methodological 
guidelines available compared to many other types of research (46). Several methods can be 
used in case studies; the use of secondary data and data analysis, structured surveys, review of 
documents, and semi structured interviews. The first methods can be characterized as 
quantitative methods, and often answer questions of what, how many or how often. The 
quantitative approach look for consistent behaviours or „laws‟, which then can be applied to 
sets of similar examples. Document reviews can be both qualitative and quantitative, 
depending on the information. An interview, on the other hand, is in essence a qualitative 
methodology, asking the questions of how and why. This is often used to investigate causality 
directly by looking in detail at how the causal process works within particular cases (47). In 
his book, “Interviews- an introduction to qualitative research interviewing”, Kvale describes 
an interview as “a conversation where the outcome is a co production of the interviewer and 
Vaccine introduction at country level; a case study in Malawi 
 
Ellen Eie 30 
the subject”. He defines it further saying that “the qualitative research interview attempts to 
understand the world from the subject‟s point of view, to unfold the meaning of people‟s 
experiences, and to uncover their lived world prior to the scientific explanations” (49). A 
qualitative research should increase the complexity, not reduce it (50). Kvale uses Webster‟s 
definition of a conversation as; “an oral exchange of sentiments, observations, ideas, 
opinions”, and he compares different types of conversations, calling the qualitative interview 
a professional interchange, or a professional conversation. This study relies primarily on 
semi-structured interviews and document reviews, and is as such a qualitative study. It applies 
what George and McKeown calls the process-tracing approach where the decision-making 
process is the centre of investigation, and where the process of constructing an explanation is 
much like the construction of a web or network. The growth of the web orients the search for 
new pieces (46). A similar approach in the health literature is found in the area of policy 
analysis. This is a process of looking back at why and how a policy made its way onto the 
agenda and whether or not and why it has achieved its goals (51). Stakeholders are in this 
setting described as “individuals and groups with an interest in an issue or policy, those who 
might be affected by a policy, and those who may play a role in relation to making or 
implementing the policy – in other words, actors in the policy process” (51, page 177).  
Identifying the stakeholders who are, or have been, involved in a political process, requires 
the judgement of the analyst (51).  
 
The sources of information used in this case study, are documents and key informant 
interviews. (The results included are the documents and meeting minutes received from 
different sources during the field work in the autumn of 2007, together with the in depth 
interviews done in Malawi, Switzerland, and Norway.) The documents are in the form of the 
proposal from Malawi to GAVI for support, the meeting minutes from the meetings prior to 
the writing of the application, the annual progress reports from Malawi, annual reports from 
the Ministry of Health in Malawi, and documents from GAVI found on the internet and 
received during the visit to GAVI in Geneva. The interviews were conducted during a 3 
months field work in Malawi. In order to document the persons contacted, and the 
information given in the day-to-day work with the research during the field work, a record of 
events and observations was written on a daily basis. This was also in order to keep track of 
all the persons contacted, who they were, and whom they referred me to (Appendix 7). 
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3.2 Identifying stakeholders and challenges in collecting data 
 
In the book Making Health policy, health policy interviews are said to be of a special nature. 
They are sometimes called elite interviews, and they pose special challenges. It might be 
difficulties in recruiting respondents, as they may worry about how the results might be used, 
they might be very busy and have less time to give interviews, and they might be able to only 
talk about official policy issues, that might as well could have been obtained using policy 
documents(51). 
 
In this thesis, identifying the stakeholders in the implementation process in the introduction of 
new vaccines was of great importance. Moreover, the number of people directly involved in a 
decision-making process is often limited, depending on the breadth of involvement of 
stakeholders and civil society. As a starting point the application sent from the Malawi 
government to GAVI was used, together with the snowball technique using the contacts 
already established in Malawi. There was also a published working paper on the constraints, 
proposed improvements and sustainability of the EPI programme in Malawi, where the 
authors of the paper were identified as people of interest for this study. This implied having a 
few individuals to approach when the research started, and through them identify further 
informants who then in turn identified others. Some of the stakeholders identified as 
participants in the process had moved out of the country, and three of them agreed to answer 
the questions per mail. However, one of them withdrew after the questions were posed, and 
one answered only very limited to the questions. Although the persons considered to be of 
interest was listed beforehand, there was still the challenge of finding them, interviews were 
refused for different reasons, and those who at the starting point were assumed to be able to 
give useful information in some cases did not do so in the end, requiring other informants.  
 
One of the limitations of data collected through health policy interviews is that the persons 
interviewed do not necessarily give information about what the persons actually think or do. 
The information is about what they say. The importance and the relative influence of the 
actors taking part in the process, is not possible to judge, other than judging the influence of 
the organizations they were representing. It is important to mention here, that some of the 
persons, who were working for the international organizations, were Malawians, and whether 
they answered in accordance with their organization at the time or in accordance with their 
nationality is difficult to judge. When the different persons were asked to participate, they 
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were asked if they took part in the process or if they had knowledge considering the process 
although they did not take part themselves. This might have excluded more people than 
necessary, but the interviewer found it necessary for the persons to define this on their own 
part. It is believed that an interview with a person who is convinced having taken part in, or 
having knowledge about, this decision making process, would create only limited answers of 
interest. This suggests that it was important that this was defined and decided by the 
stakeholders/participants themselves. Whether the person had taken part or not in the process, 
or had knowledge of the process without actually taking part in the meetings where the new 
vaccines were discussed, was therefore the persons themselves were let to define, not the 
interviewer. If the persons contacted said they did not have the knowledge, the interviewer 
accepted this with no effort of persuasion. The persons ending up taking part in this study 
however, seems to be the key persons taking part in the decision making process.  
 
The challenge in relation to the interviews mentioned by all, were the time span since the 
meetings and the decision had taken place, and that it therefore could be difficult to recall the 
content of it all. Some asked for the questions in advance, and some did not. This is a lesson 
learnt for the author however, and the interviewer would have encouraged the interviewees to 
receive the questions beforehand in order to make the most of the interviews, if the field work 
should have been done all over again. The reason for not doing this for all the interviews 
however, was the perception that the persons to be interviewed were very busy and their time 
taken for the case study should be limited to the interview itself. 
 
One consideration before going to the field was that the topic for this research could be 
sensitive, in regards of questioning the introduction of the new vaccines at a time where it is 
evident that the prices of the vaccines has not dropped as hoped and the financial challenges 
are prominent. However, the respondents gave little impression of this and it was the 
impression that they talked freely during the interviews, although the situation was limited by 
time, as they all had very tight schedules. When the time for the field work was going towards 
the end, the circle of people was closing in. The different persons the interviewer had been in 
contact with referred to each other and to the same people who had already been interviewed. 
It is the impression of the author, therefore, that although finding the people to interview 
could pose some challenges, the key persons for the purpose of the study, were the ones who 
actually took part.  
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One important consideration seen in the aftermath of the fieldwork, however, is that with the 
results in hand, the impression is that the decision making process is still going on. The 
process has not ended. With this information in hand during the field work, the persons 
judged as taking part in the decision making process would have been different as this would 
also include the persons working with immunization today. Some of the persons taking part in 
this study are by coincidence working with immunization also today, but with the judgment 
described above; this would also have influenced the content of the questions asked and the 
group of people approached.  
 
More time than expected also needed to be used in getting a research permit from the Ministry 
of Health in Malawi. An ethical clearance from Norway was not necessary, and unfortunately, 
the information that a research permit was needed was not in the hands of the author before 
arriving in the country. An application could only be submitted on certain dates and the 
Ministry of Health needed several weeks of considering the application. The advice from 
several key informants was not to contact the persons of importance for the interviews before 
this research permit was in hand, in order to avoid unnecessary offence. However, this had to 
be done in the end, in order to be able to interview the “right” people during the time schedule 
laid out for the field work (Appendix 1). 
 
From the outset, there were around 20 names on the list of persons who could be of interest to 
this case study. After arriving in Malawi, it became evident that many of these persons were 
no longer in the country, and new names were added to the list that was not mentioned in the 
applications or any of the reports in hand. The principle made for the time in the field was to 
contact all the people whose names were given to me, and trust them if they said they had 
knowledge of the process, and also if they said they did not. Although the list of persons 
interviewed became considerably shorter than first anticipated, it is believed that the key 
persons who worked with immunization in Malawi at that time, and who also work with 
immunization in Malawi today, were available and answered to the questions extensively. The 
persons interviewed were asked to give their verbal consent before the interviews started 
(Appendix 2). 
 
To increase the understanding of the topic and the validity of the results, three meeting 
minutes from the period the Malawi government and the international organisations through 
the ICC committee, are also being used. There are other meetings described in the application 
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from Malawi, and there have been made extensive efforts from the EPI manager in the 
Ministry of Health in Malawi to get hold of these minutes, but unfortunately this was not 
possible. The three minutes that are used, are described in the application as the most 
important ones (Appendix 8).  
 
3.3 Analytical framework and study design 
In the GAVI effectiveness paper by Sandberg and Bjune, (1) this framework on vaccines and 
immunization has been used with the rationale arguing the need for a political perspective on 
global health governance without reinventing the wheel. As a pilot for part of the SUM-
MEDIC research project, this study makes an effort of applying the analytical framework 
from studies of environmental regime implementation to the introduction of new vaccines at 
country level. In a paper by Sandberg and Bjune, the national circumstances between and 
within countries suggests that there is no single way for a country to put its international 
commitments into practice. Like environmental problems, many health problems are 
international, their causes or consequences cross political borders. To combat these problems 
requires coordination among states (3). When actors decide to coordinate their actions to 
solve a problem, they need to agree on a solution, and the implementation will depend on 
each partners will and ability to adhere to the agreement. Regime studies looks at how 
cooperation works in practice. Regimes can influence the behaviour of partner agencies and 
members, they are not actors in their own right, and the effects following regimes are changes 
in partner‟s interactive decision-making. This can be considered outcomes of regimes (4).  
There are many factors influencing the behaviour and effectiveness of international 
commitments; the nature of the problem at hand, configurations of power, the nature of 
commitments, linkage with other objectives and issues, exogenous factors, public concern, 
and national and international organizations. International institutions are established 
principles and processes for making decisions and can therefore lead to more effective 
international cooperation. Institutions can be looked upon not only as organisations but 
include arrangements for cooperation, sets for informal and formal rules prescribing roles and 
responsibilities, and do not act on their own, as organizations do (4). They are sometimes 
equated with regimes, and are often used interchangeably. Like in international environmental 
commitments there are many factors influencing the international health commitments as 
well. Therefore research aiming at tracing cause and effect can be difficult (3). The political 
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challenges arise once you move away from a situation where actors share the same 
preferences, interests and values about an issue. Regimes can also affect actors differently, 
because actors have different perspectives from which they judge costs and benefits and 
because the material consequences can differ. The cooperation can also be determined by the 
institutions problem solving capacity, which can be defined as the extent to which the 
institutional set up can provide incentives for partners to adjust. This is further decided by the 
institutional setting, the distribution of power or authority among the actors involved and the 
persuasion and skills within an institution exercised by leaders or experts (4).  
The assumptions this analytical framework (and the experiences on vaccines so far) create is 
that as a global institution, GAVI will ease cooperation among partner agencies in countries‟ 
decision making processes on new vaccine introduction. GAVI partner agencies and 
stakeholders in Malawi are likely to see new vaccine implementation differently. Therefore, 
their will and ability to adhere to GAVI agreements is likely to differ.  
The study objectives, as presented in the introduction, formed the basis of an interview guide 
in order to ensure consistency and reliability in the interview situation. This also served as a 
guide to structure information from documents. The interview guides were adjusted according 
to which stakeholders were being interviewed. Thus, the global partner representatives had 
slightly different interview questions guiding the interview, than the country representatives 
from Malawi (Appendix 3, 4, 5, 6). 
The objectives set for this research, give room for interpretations. For further ensuring 
consistency and validity of information it is important to define variance on key variables.The 
concept of „new practices at country level‟, for example, will not only be concerned with the 
technical part of vaccination, but will also include the new financial aspects of the 
immunization programme, and is seen as if the existing immunization programme had to go 
through extensive changes in order to make the new vaccines “fit in” to the original EPI 
programme. This will also apply when the topic of „changes in the existing immunization 
programme‟ are being discussed, where changes can be defined as “to make different in some 
particular” (52 ), in this case make the EPI programme different from what it was experienced 
to be prior to the introduction of the new vaccines of Hep B and Hib. However, these 
variables were left open to interpretation by interviewees, and therefore not given a strict 
definition. In this way, the interview guide sought to mirror environmental implementation 
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studies in key aspects, yet keeping some variables wide, and thus be open to the possibility 
that the data on Malawi and new vaccines might reveal new insights into the policy process 
 
The concept of problem solving capacity is borrowed from Sandberg et al where they in their 
studies use Miles et al‟s clarification of the concept where problem solving capacities are the 
tools available to an institution to direct and adjust collaboration. This capacity is 
conceptualized as power, persuasion, and the institutional setting. Power, or authority on the 
part of individuals or actors, can be an effective tool in situations where there is a big 
difference in actor‟s positions.  Power may be the ability to influence issues important to one 
self (autonomy), or the means to influence others. Power can also be an informal source of 
leadership. Studies of environmental regimes show for instance that the less formal authority 
is vested in a secretariat, the more important are informal sources of leadership. The 
institutional setting is the operating procedures for reaching decisions. One can view 
institutions as a framework that regulates access to the decision-making table, and the kinds 
of problems that are decided upon. In this way, the design of regime may influence actor‟s 
willingness to agree on what to do and how to do it, merging diverging positions into 
collective decisions about solutions (4). The concept of regime will be discussed further in 
chapter 3.3. 
 
The term adequate can be defined as “sufficient for a specific requirement”, according to the 
Merriam-Webster Online dictionary. The specific requirement in this case study could be seen 
as the decision making process taking place, where the optimal goal is that the process ends 
with an informed consent, where sufficient and adequate information was provided and 
received concerning the different topics being discussed. The concept was, at the outset of the 
interviews, not given a strict definition. It was seen as most appropriate to let it be defined by 
the stakeholders involved in the process and learn if they experienced the information flow 
satisfactory according to their expressed or not expressed need for information (52). Norms 
could be defined as a principle of right action binding upon the members of a group and 
serving to guide, control, or regulate proper and acceptable behavior (52). In the GAVI-
effectiveness paper, the prevalence of a disease within a country or region is said to be the key 
information that for national governments can justify the introduction of new vaccines. This 
information demonstrate the extent to which the disease targeted by the vaccine is a public 
health problem, and thus informs if immunization will be cost-effective and bring public 
health gains. Such studies are a norm in middle- and high income countries and with the Hib- 
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vaccine, this was increasingly also advocated as a norm for decision-making processes in low-
income countries (4). It this case, the norm is not a binding principle of action, but more of a 
guiding one.    
Norms can be seen as implicit rules underlying cooperative behaviour and regularity of 
behaviour, or a tool for coordination.  Norms can also be defined as “standards of behaviour 
defined in terms of rights and obligations” (53). Norms can also be explained in the following 
“a variety of norms serve to guide the behaviour of regime members in such a way as to 
produce collective outcomes which are in harmony with the goals and shared convictions that 
are specified in the regime principles” (54).  
 
The interviews were recorded and transcribed immediately after they were done. As English 
is the official language in Malawi, an interpreter was not necessary. The respondents were 
informed on how the information given would be used and that the respondents would be kept 
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4 Results 
 
In the following chapter, the results from the field study will be presented. Many actors and 
organizations are involved in this case study. The ICC committee, which was one of the 
starting points for the mapping of the stakeholders, will therefore first be presented. In order 
to keep track of important moments in the decision making process, a chronology over the 
decision making process will follow, with an explanation of the importance of the different 
moments in time. The chapters following the chronology, are organized in accordance with 
the study objectives and the interview guide, although some chapters have been put together 
in order to give a more organized presentation. The persons interviewed are classified and 
referred to according to the following; Country Representatives (CR), In Country Partner 
Representatives (ICPR) and Global partner Representative (GPR). The “i” with the following 
number is for the author to identify the interviewees.  
 
4.1 The stakeholders 
 
The members of the ICC committee in Malawi at the time of application for the support from 
GAVI are illustrated below. 
In the meeting minutes from the meetings prior to the application was sent, the actors taking 
  ICC 
National EPI manager 
 







Services   
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part in the discussions expressed the desire to include more stakeholders  in the process, 
specifically mentioned; DANIDA, KFW, and NORAD, also outlined in the figure above, 
although not “attached” to the ICC. These were accordingly also of interest for this case 
study, however, the first two did not take part in any of the meetings prior to the application 
sent according to the meeting minutes obtained, and the latter was reluctant to be interviewed.  
 
4.2 A chronology over the decision making process. 
 
The results from the interviews suggest that a few main actors in the different steps of this 
process are more or less the same throughout the process, and many of them are also working 
with topics related to immunization today. It was also discovered information which indicates 
that the decision making process is a continuous process which is still going on, as the 
funding of the immunization programme in Malawi is not secured for the time after the GAVI 
support, and the prices of the vaccines are still relatively high.  
There were different moments pointed out by all the respondents as important happenings 
which had and still has, influenced the process. In order to clarify to the reader the concept of 
these moments and when they took place, a time line is presented with a justification of why 
these moments were important in the decision making process. 
 
The establishment of the Inter-Agency Coordinating Committee (ICC)  
The date of the constitution of the ICC committee in Malawi is given as 29
th
 April 1998. It 
was established as a permanent committee which should assist in decision making for the 
overall functioning of the Expanded Programme on Immunization (EPI). The background for 
the establishment was the need to follow up the polio eradication immunization days and to 
focus the efforts in the control of measles. The donors and Ministry of Health suggested the 
following be members of the committee WHO, UNICEF, the Department for International 
development (DFID) in UK, ROTARY, Japan International Cooperation Agency (JICA), 
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Development Cooperation (NORAD), Ministry of Health (55). With the exception of 
NORAD, these are also the members who constituted the ICC committee and who composed 
the application sent to GAVI. 
 
One interviewee says the following of how the ICC committee was established on the basis of 
all EPI partners and who they were;” ….and you could be an EPI partner if you were a donor, 
or if your contribution was funding or technical assistance” (i9.ICPR). The respondents were 
not able to remember exactly when and how the process of taking in the new and under used 
vaccines started, but the ICC committee was mentioned by several to be the starting point, 
although they did not give any date or year of its establishment. Several of the respondents 
knew of the Hep B vaccine, and some of them had heard of the Hib vaccine although this was 
referred to as the “new vaccine” in the cases it was mentioned. One country representative 
said the ICC committee was established in order to support the polio eradication, and that ICC 
was not set up for GAVI, but that GAVI strengthened the operational and functionality and 
seriousness of the ICC. (i4.ICPR). The meeting minutes attached to the proposal to GAVI 
states more specific the time line here, as referred to above (55). 
 
The establishment of a proposal to GAVI from Malawi 
The GAVI proposal for Malawi was sent in February 2000, and it was approved from GAVI 
September 1
st
, 2000. Malawi launched introduction of the new vaccine (DPT-HepB+Hib) on 
29
th
 January, 2002. The country has given in an annual progress report every year since 2001 
(the report from 2007 is still not on the GAVI website) (55, 56). 
One of the country representatives refers to the beginning of the writing of the proposal as the 
actual beginning of the decision making process (i2.CR). Several of the respondents refer to 
the WHO annual meeting with the EPI management as the place where the news about the 
possibilities of receiving support for new and underused vaccines came up. Apparently, it was 
then discussed further in the MoH, before the information was presented at the ICC meetings. 
The time was stated to be late 1999 or early 2000 (i3.CR).  According to one central 
informant, the proposal was written by MoH, then endorsed by the ICC committee, and then 
sent to GAVI for approval (i2.CR). 
 
The establishment of the Financial Sustainability Plan 
The request for a financial sustainability plan seems to have been important for new and 
further discussions concerning the future financing of the immunization programme in 
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Malawi. The pilot for the first financial sustainability plan from GAVI was established in 
2003. The eligible countries were asked to give in their financial sustainability plan in the mid 
term of the period of support, and Malawi submitted their first financial sustainability plan in 
2003 (55, 56). One country representative describes the introduction of the Financial 
Sustainability Plan in the following: 
“(…)Initially there were no major arguments, until maybe, 2 or 3 years later, yes, when we 
got a communication from GAVI that we were supposed to write a financial sustainability 
plan, implying that oh, we went into something very expensive without knowing how we would 
manage that. So some people were saying that we wish we had started that discussion right at 
the beginning so that we could see the implications.” (i2.CR) 
 
Several of the country representatives mentioned that the request from GAVI for a financial 
sustainability plan came as some sort of a surprise. Most of them said that the discussion of 
sustainability, both as a concept and as a challenge for the country, were not discussed in any 
detail during the decision making process, but it nevertheless came up as a substantial issue 
during the interviews. This will be discussed further in the next chapter.  
Another description of how the financial sustainability became an issue is cited below: 
“Now in those days, the initial days of course the cost was not really an issue, because 
government and countries saw more the positive consequences of introducing a new vaccine 
to the children of their own country, but there were very little regards to the cost implications 
to that. But now two years later or three years later GAVI began to worry what’s going to 
happen next, because GAVI is a good initiative.” (i4.ICPR) 
 
The establishment of a Sector Wide Approach (SWAp) 
Although the establishment of a Sector Wide Approach (SWAp) happened after the new 
vaccines were introduced, it can be seen as an important moment for the future financing of 
the EPI and the vaccines given in the country. The concept of SWAp was only in its planning 
process when the discussion of applying for the new and underused vaccines was taking 
place. One country representative said it was a discussion going on about SWAp at the same 
time as the discussion about the immunization programme. SWAP was to a large extent 
another way of organizing the funding for the health sector. As the new vaccines were free of 
charge for the first five years, the concept of funding was not discussed and therefore not the 
concept of SWAp, according to the same respondent. One country representative talked of 
SWAp as:  
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“(…)…the feeling at that time was that if major issues relating to EPI were put in Swap (…) it 
would be a problem. So that the organisations that were putting funds in, said (…) the funding 
should be set aside for EPI, but I think there was quite some discussion on that, because the 
ministry wanted all the funds in one pot, and some organisations said no. It takes quite a long 
time for government to give funds to departments that require assistance, so the feeling was 
that the EPI would get the funds directly from donors, of course passing through the ministry 
of health, but it would be like special funds for EPI( ...) not all organisations were willing to 
put their money to the Swap basket at the time, it was quite an issue, others said no, what we 
will do is we will just buy into what is in the basket, I mean what the plans of the Ministry 
have made, and say, we are going to support this, funds will go directly to that.” (i1.ICPR) 
 
One country representative had taken part in the discussion of SWAp in the ministry and gave 
more information concerning what the discussion was all about. He talked of SWAp as an 
operationalization of the EHP and said that SWAp is basically one shared goal where EPI 
featured heavily.  
Seen in retrospect, now that the concept of SWAp has existed for a while, the EPI programme 
still has remained a priority for the Ministry of Health, according to one country 
representative; 
 “(…) the issue has just come in about two years ago. The issue of Swap, and the procurement 
of the vaccines, it’s just recent that we want to incorporate it into Swap. But when we were 
introducing the new vaccine it was purely known as a program issue.”  i5.CR). 
 
Another country representative expressed the concern they had because the SWAp concept 
would implicate that it would be the government who should purchase the vaccines, and no 
longer UNICEF who had done it for years, and this was to a certain extent a worry in the 
discussion.  
Some respondents expressed concern that the introduction of SWAp would have negative 
effects on the EPI programme, which until this time was seen as a well functioning vertical 
programme, but that SWAp could have effect on the awareness of the financial side of 
vaccination as well; 
“(…) efforts are still being settled on all the issues but also the Ministry does realise that EPI 
is also a major component of the serving of the child, because if it did not, then since the 
SWAP started we could have had no vaccines. So on top of all the other priorities that we 
had, it still recommends that EPI is also one of the key issues that had to happen. Before 
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SWAP, for someone to know how much it would cost, because the funding would  just came 
from the DFID and then go, so the people would just see the vaccine, but now they actually 
see how much they have to bring out of the basket, outside, but it has always been prioritised 
and that’s why I think it has really been successful.” (i3.CR) 
 
The bridge financing 
Some of the respondents talk of the bridge financing as a topic that came up when the request 
came from GAVI for the eligible countries to give in a financial sustainability plan. There was 
a discussion concerning whether Malawi would be able to start contributing a certain amount 
and then increasing it successively until GAVI could finally phase out, or if they should make 
an effort to be able to pay one certain amount and then stick to that flat out, and then rely on 
the prices of the vaccines declining. One country representative dated this discussion to be 
taking place around 2004 (i3.CR, i5.CR). The concept of bridge financing, or co-financing 
became an issue in Malawi as the support came to an end towards 2006, and the Government 
has so far committed to an annual contribution of 20 % of the total cost of the pentavalent 
vaccine, beginning 2006. The national health delivery systems will be strengthened to ensure 
high national immunization coverage. Therefore, continued financial support from partners is 
still required in order to sustain the provision of the pentavalent vaccine and for strengthening 
of the health delivery systems (57). 
“(…) the program is heavily donor dependent. Until last year when the government at least 
contributed something, because of the bridge financing, the government contributed about 1 
million, so this time around, this year we have contributed around 500 000, close to 500 000 
US$.” (i5.CR) 
 
One alternative outlined by one country representative was to go back to the previous 
programme, without giving the Hep B and the Hib vaccine, if the funding of the vaccine is 
ending. This is described further in the next chapter. Another in country partner representative 
describes the changes as follows: 
“We learned a little bit from our experience. GAVI phase 24 has been designed with two 
major changes in the process, number one; it’s not five years it’s ten years,(…) because we 
learned, we got burned, and we learned that to expect the prices to tumble from a monopoly 
                                                 
4
 GAVI Phase 2: Starting in 2006 GAVI will likely follow a somewhat revised set of policies to reflect 
experiences gained in phase 1 and evolving priorities and adaptations. The contents of phase 2 policies and 
priorities are still being defined. 
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position in as little as five years was unrealistic.(…) prices tumbling when there are two 
manufacturers, and eventually three four or five, in a ten year period, gives us a better chance 
of being right this time. And number two; vaccines are not free anymore. There is co-finance, 
co pay price which has been attached to those new vaccines, which is, admittedly, symbolic, 
it’s not very much money, 30 cents a dose, but we feel that, critical, that Ministry of Health 
and Ministry of Finance, establish a budget line for this vaccine today, when they start 
receiving this vaccine from GAVI, so that when that GAVI support ends, they have already 
been accustomed to going to the treasury including a budget line, so that it doesn’t… The 
shock is when you go from zero to something, but it’s not so bad when you go from this 
something to that something (…).” (i9.ICPR)  
 
4.3 The organization of EPI in Malawi and the entrance of GAVI 
 
4.3.1 The EPI programme 
All the respondents talked about the EPI programme in Malawi as a successful programme, 
and the country representatives and the in country partner representatives were very proud of 
what they had achieved. Some reasons for the success were said to be that the EPI programme 
did not have so many partners and that it was a vertical programme in the Minister of Health, 
and therefore was very independent of the other programmes going on in the ministry. It was 
also said that because they could manage the programme with the use of health surveillance 
assistants (HSA) instead of nurses and doctors in many areas, the health workers crisis did not 
hit them as hard as in many other areas of the Ministry of Health. Another reason mentioned 
by one in country partner representative for the success of the immunization programme, was 
that after a while this programme functioned very well. Donors would in general like to put 
their money, and names, into something successful, so that their organisation can show that 
their money is being useful, and so the donor community was eager and willing to put money 
into the programme.  
  
When the persons involved in this study were asked which factors had contributed to the high 
immunization coverage given, the importance of Health Surveillance Assistance (HSA) was 
again mentioned by almost all the respondents as an important explanation. The EPI 
programme has also been successful in explaining the importance of immunization to the 
mothers in the district, or the social mobilization, as one of the country representatives called 
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it, and they have been able to build faith in the programme. Malawi‟s outreach activities were 
also mentioned as contributing factors, because it makes the walking distance for the mothers 
shorter. It was also mentioned that Malawi very rarely had stock outs of the vaccines, so the 
mothers did not experience the situation of reaching the health care facility and then the 
vaccines were not there. The fact that the vaccines are free of charge was also said to be 
important. One in country partner representative gives three main contributing factors to the 
high immunization coverage; strong leadership from the government, the role of the Health 
Surveillance Assistance, and the donor coordination around the interagency coordinating 
committee lead by the Minister of Health. Another country representative explained it by the 
dedicated EPI manager, with good support in MoH, strong district structure and generous 
funding from the donors, as the main contributing factors for the current immunization 
coverage. 
 
According to all the respondents, UNICEF was the major procurement agency for the 
vaccines, although some mentioned that this was now changing, and that the MoH was in the 
process of taking over. When UNICEF procured the vaccines, the funding would go directly 
to UNICEF one country representative said. The funding as it is now will go to the 
government who will do the procurement, while the EPI will take care of the transportation of 
the vaccines to the districts. The Central Medical Store was, during the field work in Malawi, 
going through some reformations so the organising of the procurement was not all clear 
according to one of the country representatives. This was also described as an effort to try to 
move away from using UNICEF as the main procurement agency, to a situation where the 
Ministry of Health buys the vaccines directly from the manufacturer, and put it under Central 
Medical Store. The same country representative said they had never experienced any stock 
outs of vaccines. Another country representative mentioned that the BCG had been stock out 
once, but that this was due to a problem world wide, not for Malawi only. One country 
representative expressed concern on how the Ministry of Health was going to manage the 
procurement after the introduction of SWAp, and that direct procurement from the 
manufacturer could be a challenge. The factors of greatest concern, he said, were the 
continuous funding of the vaccines, adequate logistics for procuring the vaccines, and people 
trained in actual procurement; the expertise to see it through. One in country partner 
representative said that transport is and will be the most important factor that have or may 
disrupt the existing supply system.  
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4.3.2 The entrance of GAVI 
Implementation of new vaccines at community level  
Several of the country representatives and the in country partner representatives said the new 
vaccine did not affect the existing immunization programme very much, or that little change 
was required. The effects mentioned by two central persons in the process, were that there 
was a need for new training guides to facilitate the training, and with the help of the health 
education unit, come up with some publicity material, and also a chart showing how the new 
vaccine fitted in the already existing programme.    
“At community level there was the IEC, Information, Education, and Communication, to get 
the information about the new vaccination out to the community so they would not be 
confused.” (i6.ICPR) 
 
It was also important to make sure the health workers understood that they were now giving 
five antigens, not only three. A new EPI manual was published with the introduction of the 
new vaccine, and with the help of GAVI the syringes were changed from reusable, to non 
reusable or disposable syringes. The same country representative called the introduction a 
smooth transition, as the new pentavalent vaccine fitted well into the existing immunization 
programme. One country representative talked about the reporting system also being changed 
with the introduction of the new vaccines, explaining the drop in the reported immunization 
coverage in 2002.  
“The practical doing was no change, it was nothing, it was the same thing, we were giving 
three doses to a child, in fact people didn’t notice anything, no change, the same thing, the 
only change for us, maybe the size of the vial, that’s all, this time around it’s small, but there 
isn’t much.” (i5.CR) 
 
Representatives from GAVI had in many ways the same answers to this question, but also 
mentioned improvement of the cold chain system as something that had to be done at 
community level. An in country partner representative sums it all up in the following; 
“I mean it takes about six months to get ready to introduce a new vaccine, you have to reprint 
the vaccination cards, prepare all your monitoring systems, you have to check your cold 
chain to make sure you have space to accommodate, to train your health workers, information 
packages for the general public, and for the public health community as well, cause you need, 
doctors, nurses, everybody must be on your side and behind it, hmm…you know by the time 
you receive the vaccine and send it out to the districts and get ready for day one, we used to 
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recon about six months. So, technical agencies like WHO we would concentrate on making 
sure the government was ready. That was our concern.” (i9.ICPR) 
 
Consequences for the national health system 
This was a question several of the respondents from all groups, found hard to answer, and the 
question could also be interpreted in different ways. One central person in the Ministry of 
Health said that there were hardly any consequences for the national health system, because 
that was the job of the Ministry of Health, to make sure the new introduction did not create 
chaos in the system. He explains this further by saying that in order to avoid this, you need to 
know the system well, and because they applied for the pentavalent vaccine only, they did not 
have to make any big changes. Asking the mothers to come for new shots would have shaken 
the system, and therefore the ministry tried very hard to avoid this, and applied for the 
pentavalent vaccine. Two other country representatives pointed at the reduced incidence of 
Hib meningitis after the introduction of the new vaccine as positive consequences for the 
national health system.  
“Well in Malawi, really, EPI really didn’t have much impact in health systems, because 
coincidently Malawi has more urgent issues to be solved from an instant point of view, and 
that was HIV/AIDS,  and because EPI delivery system is so specific that you can actually, and 
this is demonstrated, you can actually make it work without the system work, because it is so 
specific, you need a cold chain, the vaccines has got the cold chain, you need the specific 
vaccine, you have the injectable vaccines, the oral vaccine, so this is one of the examples, and 
good  examples in the world, that you can have a very successful vertical program, EPI, 
without a system functioning above, and Malawi demonstrates that.” (i4.ICPR) 
 
GAVI; the organisation now and before and how to reach agreements 
One global partner representative explained the history of GAVI as follows; there was strong 
criticism towards WHO and UNICEF for not taking responsibility when it came to new and 
underused vaccines and little had happened in the vaccination area since the 1980‟s. To 
achieve results quickly, and efficiently, a new Alliance was created, were the partners should 
have the responsibility to do the tasks, and that the Alliance should only have a small 
secretariat, and no offices in countries; no country representation. It started out with one man 
and 50% secretary work, and during the first year, built up to five professionals, and three-
four secretaries. They were based in the basement of UNICEF, and had a banc account of 750 
million US$ from the Bill Gates foundation. There was pressure on the Alliance to choose a 
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few pilot countries, and scale up their immunization programme first, but this was rejected by 
the starting group of GAVI, they wanted to have a quick scale up for all the countries who 
were defined as the poorest countries in the world with a GNP per capita below 1000 dollars a 
year. During the first year of GAVI‟s existence, they had approved the proposals from 50 
countries, and when the results began to show, it was the Gates foundation that suggested 
prolonging the programme. The intention was to make the GAVI Alliance redundant. The 
criteria for being an eligible country have more or less stayed the same during GAVI‟s 
existence according to this respondent. There was in the beginning a discussion concerning 
how the different members of the Alliance should be organised. One reason for this was 
because the mandate an organization has on a global level, can be different from what they 
have on a national level. The role and responsibility of the members of the Alliance is 
according to the role of their so called comparative advantage and this has not changed to any 
extent since the start.  
 
WHO and UNICEF are described as the main actors in the ICC by one of the global partner 
representatives, and they are also two of the principal partners in GAVI, according to one of 
the in country partner representatives. WHO and UNICEF are the two agencies that run the 
decision making body that directs GAVI and therefore the information distributed by GAVI 
must be harmonised and consistent with WHO and UNICEF. He further states:  
“(…) and therefore information distributed by GAVI must be harmonised and consistent with 
WHO and UNICEF, and I think it is. I’ve never seen an example where there’s any significant 
discrepancy, and I can’t think of any example, they go to some trouble to make sure it’s all… 
And don’t forget GAVI doesn’t have field staff, WHO has people in the field, UNICEF has 
people in the field, GAVI doesn’t have, they only have its staff here, you just met them, they 
don’t have any field workers. They go to countries, but they don’t have people there who, you 
know, could possibly develop a different message, I couldn’t see how that would be (…)” 
(i9.ICPR)  
 
One in country partner representative said that WHO is governed by the ministries of health 
in the member state countries, who forms the general assembly, which determines the work of 
the executive board in Geneva. The ministries of health wanted WHO to be an active partner 
in GAVI, and the member states will drive the agenda, according to this in country partner 
representative. Another global partner representative emphasized the communication between 
GAVI and the eligible countries, that the GAVI secretariat should not communicate directly 
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with the country, but that the main communication should go through WHO and UNICEF, so 
that the responsibility to communicate with the countries on technical issues were done by 
them. GAVI only did the communication concerning the application.  
 
As of how the organization works when it comes to the applications they receive, the 
following was explained by one global partner representative; the country, with the help of 
the partners of the Alliance, develops the proposal. The proposal goes directly to the GAVI 
secretariat, the secretariat is organizing a review of the independent review committee, and 
the independent review committee is answering directly to the board that will eventually 
approve if the independent review committee is recommending for approval. The independent 
review committee has technical assistance from WHO. This was necessary in the beginning of 
GAVI, when there was a concern that the introduction of new vaccines would undermine the 
polio eradication, so WHO was requested to establish a team to pre assess the proposal which 
was submitted by the country and give technical advise about whether the country was giving 
the right considerations to the polio eradication activities, vis-à-vis the activities for the 
introduction of the new vaccines. There were also other pre assessments done like injection 
safety, availability of vaccines, and financial sustainability plans. In order to elaborate on how 
the GAVI Alliance has changed, he further says that in the beginning GAVI did not ask many 
questions to the counties on injection safety, then they started to ask the countries to give in 
documentation on this, then they started giving injection safety support, only for three years, 
and most of the countries continues to have a focus on this after the three years have ended, 
some also expand it to the entire health sector. According to this global partner representative 
the requirements of GAVI will keep modifying by building on what is the capacity the way it 
is developed in the country.  
 
Advocacy  
It was said by one in country partner representative that tonnes and tonnes of advocacy was 
done for the new vaccines, in terms of websites and publications. Another global partner 
representative specified it further by saying that it was important for GAVI to make sure the 
countries knew that the vaccines were available, that they knew of the recommendations from 
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GAVI’s contribution to immunization in Malawi 
As one mentioned earlier, GAVI‟s contribution could be the strengthening of the 
functionality, operationality and seriousness of the ICC. Other than that, WHO‟s Reaching 
Every District (RED) approach was mentioned, because the percentages that are not reached 
for immunization, is often not reached because the places they live are difficult to reach. One 
of GAVIs major contributions was mentioned as the support for infrastructure for 
immunization services. The possibility to increase the reward for every additional child 
vaccinated in order to increase the immunization coverage, was also talked about as a 
solution. The issue of health system strengthening could also be a contribution from GAVI;  
“ (…) then there is the system of health system strengthening (HSS), you know there are so 
many barriers in the immunisation which are not restricted to immunisation, and the root of 
those barriers are belonging to the system, the health system, so the issues of having initiated 
giving these countries the possibility to address those barriers for sure will have an impact on 
the actual consolidation on the immunisation programme, to make it stronger and able to 
achieve what now it becomes much more difficult to achieve.” (i8.GPR) 
 
When asked if the position of the immunization programme in Minister of Health and 
Population had changed before and after GAVI, one respondent answered that the volume of 
the focus has changed, being more focus on it now than before, but the reason for this he said, 
was more due to the increased focus on the Millenium Development Goals (MDG) than the 
existence of GAVI, although GAVI had helped increasing the focus in the decreasing of 
meningitis cases. Another one said, the attention of the programme had increased because of 
the increased cost of the immunization programme after the introduction of the new vaccines. 
The concept of SWAp was also given as a reason for the increased attention on the cost of the 
programme. Several country representatives said the position of the programme in MoH had 
more or less stayed the same.  
“So in some countries the GAVI have had a stronger impact than others, in Malawi apart for 
the supplies and financing, in terms of planning and seriousness of EPI, there’s no change” 
(i4.ICPR).  
 
Major concerns in introducing new vaccines to Malawi and other developing countries 
The concern emphasized by one global partner representative in introducing new vaccines to 
developing countries in general, was the dependency on GAVI and the donor support, and 
gave this as the reason for GAVI to introduce the concept of co-payment, where the countries 
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are required to contribute a small amount for each vaccine, already from the start. He calls 
this a lesson learnt from GAVI, in order to make the countries plan for the time when GAVI 
is longer giving support. Another concern expressed by the same person, was the management 
of the vaccines, the improvement of the cold chain, and the procurement and distribution of 
the vaccines. Another in country partner representative talks about the system barriers as the 
major concern in introducing the vaccines to developing countries. These are, according to 
him, the barriers out there that prevent vaccination from rising. He says further that GAVI ran 
a study on system barriers in Malawi where they found no system for vehicle maintenance, 
and the same time learning that the outreach programmes are very transport dependent. If you 
don‟t have adequate transport, or drivers, or fuel, then you have a problem reaching every 
district. This respondent also mentioned the shortage of health staff in the country as a major 
concern.  
 
The plan of action for the Malawi health sector, for 2001-2005, also mentions the challenge of 
religious groups such as Apostolic Faith and Zion who do not allow their members to receive 
immunization. During the rainy season some areas are also impassable, which denies the 
children in these areas to complete their immunization in time (58, 59). In the Malawi annual 
report of the health sector for 2006/2007, the main challenge is said to be the procurement of 
the vaccines through the SWAp mechanism (28). The procurement and distribution of the 
vaccines and the improvement of the cold chain was also mentioned by one of the global 
partner representatives. All the reports mentioned above, mention the shortage of health staff 
as a major challenge, although this is not a problem for the immunization programme alone, it 
goes for the whole health sector. This was also mentioned by one of the in country 
representatives. The system barriers that prevent the coverage from raising is also mentioned 
by one in country representative as a challenge, and Malawi had their proposal to GAVI for 
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4.4 Political and institutional factors affecting implementation of new 
vaccines 
 
4.4.1 The influence of the actors 
Participation and personal influence 
The participation of the stakeholders was very much decided through the ICC committee and 
the members of this committee were as stated earlier in this chapter, the main EPI 
contributors. It was the Ministry of Health who chaired the ICC committee. All the 
respondents in this case study were involved in the process at the time the decision to apply 
for the pentavalent vaccines came about, although not all of them had participated in the 
meetings in Malawi. When asked about their own personal influence some of them found it 
difficult to be the one to judge their own personal influence or performance. The possible 
personal influence came out as a factor when they were asked of the reasons for success in the 
EPI programme, as their names and the role they played were mentioned as one contributing 
factor.  Here the respondents did not mention themselves, but were mentioned by other 
respondents.  
 
The stakeholders’ relation, role and interaction 
At the time of discussion concerning the new and underused vaccines, the SWAp was not yet 
on the agenda. The Malawi government and the international community had therefore not 
started the so called basket funding, and the different stakeholders had different roles 
according to what they could provide; their comparative advantage. JICA provided equipment 
to the cold chain and also funding after a while. The role Ministry of Health was more in 
terms of policy and directions in terms of how that policy can be properly implemented using 
the instructions and structure of the ministry. The EPI programme was said to be looking after 
all the immunization given in the country, looking for surveillance issues, looking for measles 
cases and neonatal tetanus cases, and take care of the National Immunization Days (NID), 
among other things. They are also responsible for the information, education, and 
communication (IEC), and to keep up the awareness of immunization in the community. The 
USAID was to a large extent responsible for the system strengthening programme, and 
provided also technical assistance. WHO supported the national programme in capacity 
building, development of annual and period work-plans, surveillance strengthening and partial 
funding for routine immunization activities. UNICEF called their role instrumental, and they 
took care of the purchase and procurement of the vaccines. According to the country 
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representatives, the ICC relies a lot on the EPI programme management technical working 
group.  
“EPI does not have very many partners because they are already performing very well…., but 
the few partners that are there, they are already so much involved in such a way that their 
participation is adequate enough for the country. ” (i2.CR)  
 
The process and the interaction between the different stakeholders is described further by one 
country representative: 
” So what is happening is that instead of having a wide achievement with technical people 
discussing issues to inform policy, at the technical level we rely on guidelines from WHO. So 
these meetings that we are talking about they were organised by WHO. So whatever we get as 
a new direction in terms of what to adapt or adopt, we discuss it, we just go for a meeting and 
ask the District Health Officers (DHO’s) and the other partners to participate, within the EPI 
program, so there is a discussion. What that discussion comes up with, conclusions, maybe 
adapt the guidelines or the generic guidelines, then ones we have adapted, the EPI program 
goes ahead with the preparation on how these guidelines should be implemented, in terms of 
what has to be procured, what has been changed, what has to be developed in training 
management and the like, so that transverse into a package. Now it is the package of what has 
to be done and how much money is required to do what has to be done, that goes to the ICC. 
Now the ICC includes all the partners like the donor partners, , DFID, USAID, NORAD, the 
UN bodies , that is participating in the EPI, to discuss, first of all to look at what we have 
agreed on activities to influence, to manage the change, or to manage the diversion of the new 
guidelines, whether we have done it in such a way that it will be cost effective. It is not a 
question of whether we will do it or not, it’s a question of whether it is done in such a way 
that it is cost effective….(…)…the next thing to be doing till we meet again, is to look at the 
financial mobilisation, how much will come from government, how much will come from….so 
we put that figures on the left column, the donors on the top column, and then whatever 
amount they put on each one of the activities, we know which are the gaps. So using that 
approach we have been very, very successful,” (i2.CR)  
 
When it comes to the actual proposal for the funding from GAVI, the Malawi government 
was said to be the owner of the proposal, and one of the requirements from GAVI was for the 
proposal to be developed in close cooperation with the ICC committee. The final signature is 
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always from the Minister of Health, but as was said during one interview, a signature from the 
health minister without the signature of WHO and UNICEF would not be good. 
 
GAVI and WHO  
One country representative said WHO provided the information needed concerning the new 
vaccines. A global partner representative gave one example of the cooperation between GAVI 
and WHO: 
“(…)in the past we had technical assistance from WHO on the issues of polio, particularly at 
the beginning, just at the beginning of GAVI, there was a concern that the introduction of new 
vaccine would have minimized the whole of polio eradication which was actually still a 
concern in most of the countries, so WHO was requested to establish a team that could pre-
review, or let me say, it’s  not correct the word pre-review, but pre assess the proposal which 
is submitted by the country and give a technical advise about whether the country was giving 
the right considerations to the polio eradication activities, vis-à-vis the activities for the 
introduction of the new vaccines, so that was one of the issues that was relevant for them.” 
(i8.GPR)  
On the question of whether this role had changed before and after GAVI, one in country 
partner representative explained it in this way; WHO is a sort of cooperation designed by the 
workers, WHO is governed by the ministries of health of the countries, the 90 member states 
who form the general assembly which determines the work of the executive board with the 
headquarters in Geneva. The ministries of health wanted the WHO to be an active partner in 
GAVI, and it is, so you know, the member states still drive the agenda (i9.ICPR). 
 
4.4.2 Toleration of dissent 
One of the questions asked during the interviews were if there had been a lot of discussions 
when the meetings took place concerning whether the vaccines should be integrated in the 
immunization programme or not. This was denied by most of the respondents. In fact, all 
except from one said they all agreed it was a good idea, and if there were any discussion, it 
was more concerning the practical side on how to implement the new vaccines.  
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4.4 The role of international norms on new vaccine introduction  
 
An important part of the standards of behaviour or norms in the vaccine introduction process 
is the exchange of information and technical advice between WHO and countries, and 
between GAVI and countries, and the presence of information expected to be part of the 
decision-making process. 
 
4.5.1 Facilitation of adequate information  
Although the term adequate in this case study can be seen as sufficient information provided 
and received concerning the different topics being discussed in the decision making process, 
the concept was, at the outset of the interviews, not given a strict definition. It was seen as 
most appropriate to let it be defined by the stakeholders involved in the process and learn if 
they experienced the information flow satisfactory according to their expressed or not 
expressed need for information. On the topic concerning adequate information, the 
respondents are asked where the information came from, what kind of information Malawi 
asked for, what kind of information Malawi was asked to provide and information between 
GAVI and countries, and the responsibilities of WHO in that setting. 
 
From the WHO point of view, the important information for them to receive from the country 
was information concerning if the government was ready to introduce the new vaccine. The 
respondents talked about the need for information as different now, and in phase 1. In phase 1 
the important information for GAVI to give to the countries were concerning what a good 
application was all about, and what were then criteria for support (i7.GPR). On the question 
concerning where the information came from, most of the respondents answered WHO and 
UNICEF. The information concerning the specific application from Malawi was given from 
GAVI, and also offered on request if needed. It was also mentioned that some information 
came from within the EPI programme, especially the official national statistics, and 
information concerning the national immunization days.  
 
One of the global partner representatives said the important thing was that the countries were 
aware of which vaccines were available, and when it came to Hep B, to make sure the 
countries were aware of the recommendations from WHO that the World Health Assembly 
had made a declaration that every country, except for a very few, were recommended to take 
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in the Hep B vaccine. This was a bit different for Hib, as the recommendations concerning 
this disease were built on the rapid assessment
5
 of the disease burden. (This has changed 
however, with new recommendations from WHO advocating the desirability of Hib use in all 
countries (14). He also mentioned that it was important for GAVI to receive the plan of the 
countries vaccination programme. It was more important to know of the different constraints 
in the system which could be a potentially obstacle for the immunization coverage, than of the 
disease burden, he said. (i7.GPR). Another global partner representative said that WHO had 
now come out with a general recommendation concerning the Hib vaccine as well, without 
having any information on disease burden. (i8.GPR). The respondents were not clear on what 
kind of information Malawi asked for, instead they answered yes on the question of if the 
information flow was adequate and sufficient. When representatives from GAVI was asked 
what information was important for them that the countries were provided with, they 
answered that it was important that the countries knew of the criteria for support, and how to 
write a good application. After phase 1 had started, it was further important for GAVI to 
receive a progress report, financial sustainability plan, and a multiyear comprehensive plan in 
order to get information on the long term immunization plan for the countries involved. 
(i8.GPR)  
 
To give in a plan for the introduction of the new vaccines was also some of the information 
the country representatives said they were asked to provide for GAVI. The national annual 
vaccine requirement was also mentioned by another global partner representative as important 
information from the countries to GAVI. In the meeting minutes in the application to GAVI, 
the ICC members suggest that more details and clarifications for GAVI should be made 
available (55). 
 
Concerning the information flow between GAVI, WHO and UNICEF, one global partner 
representative describes it this way: 
“(…) all countries are sending by the 15th of April, normally, they are expected to submit to 
the regions and then from the regions to the head quarters, they call it joint reporting form, 
whereby they report how many children they have vaccinated or which vaccines against the 
target population and so on, so we base ourselves on this report, because our partners, main 
partners, WHO and UNICEF who are in the country will be the best agencies to verify what 
                                                 
5
 Hib Rapid Assessment Tool is used to quickly obtain data on the size of Hib disease burden. It is used by 
setting the number of Hib meningitis cases against the whole population in the district under age 5, to give an 
estimate of the incidence of this condition. 
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they are talking about in the joint reporting form and what they are raising in the annual 
progress report, if they actually match or not. (…) when the independent review committee 
verifies when receiving the annual progress report, one of the ways of verification is to see 
the consistency of these data with what has been written in the joint reporting form. The 
annual progress report is from the country, and the joint reporting form is from WHO and 
UNICEF.” (i8.GPR).  
 
An important part of information, one in country partner representative emphasized, was that 
the country had set up mechanisms to check for adverse advents following vaccination. This 
was something that WHO concentrated a lot, according to this respondent (i9.ICPR).   
One global partner representative said that today, the two important parts of information that 
is important for GAVI to give to the countries is that the eligible countries should be aware 
that there is a cost involved in applying for new vaccines, it is no longer as it was at the start 
of GAVI, that they get a donation for free for the first years. Secondly, it is important for 
GAVI to receive information on how the countries are planning on renewing and maintaining 
the cold chain system, so that by the time they will introduce the new vaccines they will be 
able to have the sufficient capacity to accommodate that vaccine and to manage it properly 
and to the standard criteria (i8.GPR).  
 
Data on disease burden  
There were few data on disease burden available from Malawi prior to the application was 
sent to GAVI. The respondents had different opinions of whether the data on disease burden 
were there or not at the time of the application, and also whether the data they had were of 
importance for the application. Several of the respondents mentioned that the data of Hep B 
were the general recommendations from WHO, and one also mentioned that Hib had been 
studied by WHO in neighbouring African countries, and that these data also could be applied 
for Malawi. There was a general recommendation from WHO and the World health Assembly 
that Hep B should be given to all children world wide, except for a few countries, and one 
global partner representative said there was also a recommendation from WHO that Hib 
should be given to all children. This was confirmed by another global partner representative 
who said that GAVI saw Hib as a big problem especially in Africa, and that GAVI had taken 
the initiative to do the rapid assessment of Hib in some African countries, and this was 
decisive in order to decide whether to take it in or not in some countries. In some countries 
Vaccine introduction at country level; a case study in Malawi 
 
Ellen Eie 58 
these data were not considered. In the application sent to Malawi, no data on disease burden 
were given, and the rapid assessment for Malawi had not been done. 
 
When asked about the disease burden on Hep B and Hib, all the respondents agreed on the 
fact that there were few data, and that these data had not been important for the decision to 
send in an application to GAVI. The data they had, had been obtained independently of the 
decision to apply for funding, there had been by coincidence, according to a country 
representative, a study done on blood donors on Hep B in Lilongwe, which showed a 
prevalence of 8-10%, and Welcome Trust had been doing their own studies in Blantyre, on 
bacterial meningitis, where they had data from five years back, which showed that Hib was 
accounting for many of the bacterial meningitis cases These studies are presented in chapter 
2.4.3  and are mostly from the time before the introduction of the new vaccines. (41, 42, 43, 
44, 45). One in country partner representative emphasized that there were no “data” on 
disease burden, only projections.  
“We didn’t, to be honest, we didn’t spend a lot of time on that issue, and the countries weren’t 
asking a lot of questions. It was…in the public health community it was I think it was widely 
understood, that liver cancer is the first cause of cancer mortality in most of Africa, therefore 
if these guys have a vaccine to prevent it; it must be a good thing. That was largely…Hib was 
even more difficult, because there was even less information about burden of disease. And, of 
course, you know Hib produces meningitis and pneumonia, and it’s very difficult...it’s very 
complicated to estimate what proportion of overall meningitis is due to Hib and what 
proportion of overall pneumonia is due to Hib, we do have some rough figures on that, but 
again, it’s pretty much estimates.” (i9.ICPR) 
 
4.5.2 Access to data on costs and benefits 
On the question if the persons involved in the decision making process had access to data on 
long term costs and benefits, most of the respondents answered no, they did not have these 
data available. One of the in country partner representatives answered a clear yes, sure, on the 
questions on if the data on long and short term cost and benefit was available, but did not 
elaborate on this further. Most of them said they did not have the data on this, and that 
especially the cost was something that came up when Malawi was asked to give in their 
financial sustainability plan, half way through the first five years. When the subject of cost 
and benefit came up during the interviews, the discussion of sustainability also became a part 
of this question. This will be a topic later in the result chapter and will therefore not be 
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elaborated further here. One in country partner representative said, that in the overall strategy 
for health, the immunization of the world‟s children is considered the most cost effective 
intervention that can be done, and that the problem is that immunization is not given the right 
level of resources which was expected to be received. This, he argues, is because the curative 
part of the health sector has had priority over the preventive part, and that when talking about 
cost-effectiveness, the curative part is very costly, and maybe more so than the preventive 
one. (i8.GPR)  
 
It was strongly believed, one in country partner representative said, that the massive increase 
in demand for the new vaccines would convince the manufacturers to allow the price to 
decline, increase the competition from other manufacturers and thereby reduce the cost. This 
has happened to the Hep B vaccine, where he gives the price of the vaccine to be 25 cents, 
declining from 100 dollars a dose in the 1980‟s.  
 
4.6 Issues raised by the respondents 
 
What is written in the previous chapters were the main issues raised in the interviews, but it 
was not, however, most of the respondents major concerns. During the question of whether 
there was a lot of discussion during the meetings prior to the writing of the application the 
answer was no. However, several of the respondents elaborated further on this later in the 
interview, and when asked of the major challenges in implementing the pentavalent vaccine, 
some main issues came to the surface. 
 
4.6.1 Sustainability  
According to GAVI‟s own evaluation of phase 1, contrary to their expectations, a five year 
period was insufficient for vaccines to become affordable and for government budgets to 
adequately expand to finance them. Some GAVI partners also believe that providing vaccines 
for free, contributed to weak national decision making. When some of the “early-adopter” 
countries were faced with having to finance the vaccine through national and partner/donor 
resources, it became clear that they had introduced Hib vaccine without first reviewing the 
evidence and deciding that it was a national priority” (60).  
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One in country partner representative said that the discussion of sustainability is now the most 
difficult part of the whole exercise. Several respondents started answering the question of 
sustainability by giving their definition of the concept of sustainability. Sustainability could 
be defined as the ability of the country to continue its immunization program in the absence of 
external support (61). One says that no government in the developing world has the money to 
finance all the interventions that has presently been financed with external money, so 
sustainability becomes more of a question of who‟s going to pay, the donors, the government 
or the users of the services. Now, if donors want to sustain the new vaccines introduced in 
Malawi, they have to continue pumping money, according to this in country partner 
representative. Malawi is genuinely poor, so in countries like Malawi, he says, donors have no 
other option. Another global partner representative said that sustainability is not the same as 
self sufficient. Sustainability, he says, is when the economic development has reached a gross 
national product of above 1000 US$, and they will be able to finance the new vaccines. This 
was contradicted however by another in country partner representative. A global partner 
representative said that sustainability is not the same as self sufficiency, but as the possibility 
for local resources both from the government and from other resources in the country. One 
country representative says that the issue of sustainability is just an excuse for not introducing 
new ideas. One global partner representative answered that until Malawi had experienced 
some economic development, the possibilities for them to take over their immunization 
programme, and make it sustainable, is an illusion. He further says that when they achieve a 
gross national product of above 1000 US dollars, they will be able to finance their own 
vaccines. One country representative emphasized the fact that the immunization programme 
in Malawi is heavily donor dependent. The issue of sustainability, therefore, was often talked 
about in connection with the commitment of the donor, and the continuous funding from the 
donor community. The sustainability depended on if the donors would be available to provide 
funds for procurement of the vaccines (i1.ICPR).  One country representative says further that 
when the question came from GAVI on how Malawi could sustain their immunization 
programme, a programme that had increased it‟s cost by 90 % because of the new vaccines, 
the Malawi government answered that this would not be possible for them to sustain, and that 
if this was a criteria they would go back to their original immunization programme. 
“What we would just tell them that actually the diseases can come back and they can restart 
as a major problem, but for the sake of what we will explain; we are no longer able to 
procure the additional vaccine which were in the same volume, because of financial 
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problems. The partner who was there before has decided to discontinue in supporting it.” 
(i2.CR) 
 
One country representative said there was little discussion on funding at the start of the 
process, the vaccines were coming for free so there were no major headaches about funding, 
and the challenge and discussion of sustainability came up when Malawi were asked to give 
in their first financial sustainability plan, mid way through the first five years of support, and 
that it was at this point they discovered how expensive the vaccines really were when 
comparing it to other vaccines in their immunization programme.  
“(…)so we had to be open in our discussions, for Malawi this is what it could mean because 
maybe had we known it would be this expensive although it is very good for the children, we 
would have waited and worked with GAVI properly, but this was like a support which had 
come in and we knew we needed it so who would say no.”(i3.CR) 
 
The same respondent says it was a good thing they started to talk of the financial issues, 
because by that time the assumption was that the prices would come down but it was 
discovered after the first phase that they‟d really never dropped.  
“(…) we are hoping for the best as we move on, because a country like Malawi with a lot of 
other health problems would not be able to pay that sort of cost, so it is a good thing to have 
the discussion of co payment with WHO and GAVI” (i3CR). 
 The alternative of going back to the old immunization programme was also mentioned as a 
solution, talking about it as a disaster for the Malawi children.  
 
All the respondents emphasized that the cost of the vaccines and financial sustainability was 
not really an issue in the initial phase of the discussions, there were little regards to the cost 
implications. One in country partner representative said that a government like Malawi at the 
time of the introduction was not really prepared to fund the vaccine that would cost them 5 
dollars, with the total health expenditure being 10 dollars. As time went on the issue of 
sustainability came up, because “everybody” had begun to worry, the countries who had 
implemented the vaccines in their immunization programme, and GAVI. As the respondent 
said, very few countries in the world will be able to cover the 5 or 6 dollars that the original 
vaccines are costing. When the respondent goes into the question of challenges for Malawi in 
implementing the immunization programme, the issue of sustainability comes on again. He 
says that Malawi has for the first time had a positive economic growth, and if the trend 
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continues they might expect higher levels of income to the government and thereby higher 
levels of finances to the health sector, but unless that happens, it is difficult to see how they 
will pay the price. He says further that immunizing the children is a part of the Millenium 
Development Goals, which GAVI is also backing, and he gives the numbers on this by saying 
that achieving the MDGs will cost approximately 60-80 dollars per person. This is not 
possible to do for Malawi alone.  
 
As mentioned earlier, the issue of financial sustainability through a financial sustainability 
plan raised the question of how Malawi was going to handle the situation after the GAVI 
support had finished, and how much they would be able to contribute. Several country 
representatives presented the responsibility between the Malawi government and GAVI like 
this; Malawi should be able to pay a fixed contribution, which was given to be 1 million 
dollar per year, and then GAVI should manage two things; to contribute the remaining 
amount of money, and to negotiate on price reduction. Another country representative said the 
request from GAVI was that the Malawi government should start contributing a certain 
amount and then increase, but the Malawi government and the Ministry of Health said they 
could only manage a certain amount flat out. They were expected to pay 20 cents per dose, 
which this respondent gives to be around 400 US$ per year. 
 
From GAVI‟s point of view, the financial sustainability plan was partly introduced to make 
the countries aware of the issue of the vaccines having a value, they have a cost, and to 
encourage the countries to start giving something. One global partner representative said the 
original plan for GAVI was to give support for five years, but then the Alliance became so 
popular, and the marked forces started to have an influence on the Alliance, and this increased 
the resources, and thereby the possibilities for the Alliance to extend their support to 15 years. 
The plan was still to have reduced prices by competition from several pharmaceuticals, also in 
the developing countries, according to this respondent. Another one explained this prolonged 
support by the influence of co payment, if the countries contribute with a certain amount, 
GAVI will be able to give support to that country for a longer time. One in country partner 
representative calls the introduction of the financial sustainability plan an interim measure to 
begin to accustom the countries to the idea that the price shock at the end of phase 1 might not 
be quite as light as we thought it was going to be.  
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4.6.2 Vaccine prices and co-financing 
The description of the situation and the “discussion” concerning the price is described in the 
following: 
“This was GAVI phase 1, so there was no what we call co-finance…. it was free. So when 
everybody turned to me as a technical, sort of, advisor, and said; ”What do you think….?”, I 
said; “ Go for the all in one, what have you got to loose?.... So I said, if supply is available, 
there were one or two supply issues around at the time, but if supply is available, why not go 
for the all in one? There is no pain for the country at all, there was no price.”(i9.ICPR). 
 
The price of the vaccine determines whether the vaccine is in or out, it‟s all or nothing, it does 
not determine coverage, one in country partner representative said. There was not done much 
in terms of cost and benefits assessments, according to this respondent. One global partner 
representative said the price reduction of the vaccines have been much slower than expected, 
even though the price of the tetravalent vaccine has been reduced by 50%. He expresses 
disappointment with UNICEF in not being able to negotiate the prices further down. One 
global partner representative said that GAVI played a role in the marked, in the sense that if 
they increase the vaccine demand, it will challenge the manufacturer, which again will give a 
drop in the vaccine prices. At the end of the 1990‟s, the expectations were that the decline in 
prices would have happened more quickly than what has shown to be the case, one in country 
partner representative said. He takes it further by saying that the vaccines should not have 
been free of charge in the first place, and calls it a bad calculation. It was too easy to take a 
free vaccine and not worry about the future, although Malawi thought about the future more 
than some countries and quite early in the process started discussing the concept of 
sustainability. It might have been better to have a symbolic charge to begin with, he says.  
All the respondents expressed optimism when talking about the future possibilities of having 
a price reduction of the vaccines. 
“We should never have given the free vaccines……Well, I think it was a, it was a, a bad 
calculation. It was too easy to take a free vaccine and not worry about the future, and all 
though Malawi did think about the future perhaps a little bit more than some countries, some 
countries never questioned sustainability, they said, “free vaccines?, we’ll take it!”(..)We 
have learned that lesson, phase 2…you know, any organisations that learns from its mistakes 
is doing a good job, GAVI has learned, we are doing it differently now.(…)There’s no point in 
blaming anyone, nobody was responsible it just happened, but it’s possible that if some of us 
with much more extensive field experience, had been consulted and had had an opportunity to 
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really influence the policies, we might have realized that it would bee better to have a 
symbolic charge for the vaccine”. (i9.ICPR)  
 
One in country partner representative emphasized the expectations of the prices of the 
vaccines coming down, he talks about the dollar vaccine and the penny vaccine, and the 
message was at the time of the introduction, that by the time the GAVI support finishes, the 
vaccines would have become a penny vaccine. The biggest issue at the beginning of the 
discussion was how to make the country ready for the introduction of the vaccine, from a 
technical point of view, and although the issue of sustainability was raised, he says, the 
countries were told not to worry, because the prices would come down.  
”…. cause that’s the trouble, you know, a little bit like private investment, you know, the guys 
tell you, this investment is going to earn you money, you know, they don’t know, based on 
previous trends they should, but the future can’t be foretold, and the same thing is true for 
these vaccines, the vaccines prices, all indications are, that all the necessary components are 
in place but the vaccines should drop in price, because of this and this and this, but, will it 
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5 Discussion 
 
The overall targets for this case study were twofold; to asses whether the introduction of Hep 
and Hib had influenced the immunization practices in Malawi and if the implementation of 
the new vaccines required changes in the existing immunization programme in the country. 
The aim was to trace the decision making process, and find out more of whom participated 
and what factors affected this process and the decision of introducing the pentavalent vaccine.  
 
Certain topics evolved during the interviews as the essential subjects of discussion, which 
suggests some main findings of the study. These are therefore accordingly, set as the main 
topics for this chapter. It is important to recognize that this study did not measure the 
respondents actual behavior in the process, instead the findings represents the respondents 
perception of these factors, together with documentations concerning the same area of 
discussion. The information given in the interviews could thus be about their opinions, even 
what they think is the right thing to say, not necessarily what they have done.  
 
5.1 The policy context 
 
The specific role of international agencies towards the national immunization programme did 
not change much with GAVI, but the policy context changed with the transition to the Sector 
Wide Approach (SWAp), as SWAp is a way of securing equity of funds to the health sector, 
and the financing issue of the immunization programme is a prominent issue in the 
discussions in the health sector. Hence, the introduction of SWAp changes the context for the 
discussions, although it did not develop as a result of the new vaccines in EPI programme. At 
the time of the introduction of the new vaccines, the EPI was a vertical programme, which is 
said by one of the country representatives, to be one of the reasons for its success. Malawi 
submitted their first Financial Sustainability Plan in 2003, and one year later the establishment 
of Sector Wide Approach (SWAp) was launched. Both factors increased the focus on the 
financial issues in the discussions. 
 
5.1.1 The position of the EPI programme in the Ministry of Health  
In the Malawi application sent to GAVI in 2000, the National Vaccine Supply Strategic Plan 
is attached where the EPI programme is called one of the priority programmes Ministry of 
Health (55). At the outset of this case study the position of the EPI programme in Ministry of 
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Health before and after the introduction of the new vaccines, seemed to be an interesting 
aspect of the discussion in order to try to find out if this had any consequences in the national 
decision making process. The results gave diverging answers and explanations, those who 
said there had been an increased focus explained it by the increased focus on the Millennium 
Development Goal, and the increased cost of the vaccine, and those who said there was no 
change in focus, did not give any further explanations for this. The EPI programme had 
already dedicated personnel, and the programme was by many called successful. It was a 
programme in the Ministry of Health which “everybody” was very proud of, and it was 
known in the donor community, in GAVI and in Malawi for its success. The existing and 
strong EPI programme was also given as supporting factors for the introduction of new 
vaccines in Thailand and Taiwan (2). It was expressed concern however that with the 
introduction of SWAp, the EPI programme could be suffering from competing programmes. 
The SWAp mechanism had only been existing for three to four years at the time of the 
interviews, so the effect of it was yet to be seen to its full extend., but also in the article from 
the University of Malawi before the introduction of GAVI, the lack of clear and unequivocal 
government commitment towards the EPI programme is mentioned as a possible contributing 
factor that has already disrupted or may threaten to disrupt the existing supply system for the 
vaccines. In order to improve and sustain the current immunization coverage, they 
recommend the Malawi Government to have the commitment to make immunization a 
priority (30).  
 
5.1.2 Role and relation of stakeholders 
All stakeholders in the process talked of Malawi as heavily donor dependent. As GAVI is 
more or less an Alliance constituted by the same actors already present in the country, with 
the private industry as an additional member, the difference in the stakeholders influence 
before and after GAVI can be difficult to judge. Like in international environmental 
commitments there are many factors influencing the international health commitments as 
well, and tracing cause and effect can be difficult.  
 
The actors, whom ended up taking part in the study, can be considered to be health policy 
makers influencing health policy on different levels in the Malawi health system. In Munira 
and Fritzen`s article, the roles and the relative strengths of the actors is said to be depending 
on the context of the policy making. Seen in relation to regime studies, some of the factors 
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that can affect the behaviour and effectiveness of international commitments is the 
configuration of power, and the public concern. It should be reasonable to say that the 
relationship between the different actors in the field of immunization is between actors of 
unequal power. Money, expertise, professional norms, and moral norms are all sources of 
power (62). According to the book Poverty, AIDS and Hunger, by Ann Conroy, international 
estimates suggest that providing comprehensive health care requires investments of at least 
US$35 or US$ 40 per capita. The Malawi Government estimates that the Essential health 
Care Package would cost US$22 per capita, but the budget for the Ministry of Health provides 
less than US$10 per capita, and it says further that it will be impossible to improve the health 
status of Malawians unless human resource and financial constraints are addressed urgently 
and comprehensively (33, page 46). In the annual report for the health sector for 2006-2007, it 
is found that from 1998/99 to 2004/05, the total expenditure on health has increased from 12 
US$ to 20 US$ per capita, and of the 22 US$ necessary for the delivery of the EHP, the 
government and donors provided 16.9 US$ (28). The exact numbers on how much the donor 
community is providing is not given in this literature, but it is reasonable to assume that if 
Malawi contributes less than 10 US$ of the total amount of 22 US$, it can indicate the 
importance of the role of the donor community in financing the health sector. As money can 
be a source of power this can also influence the role and interaction the donor community 
have with the Malawi government when it comes to decision making processes in the health 
sector. 
 
In periods were the prominence of the issue is rising, the decision making is more likely to be 
dominated by senior political figures, but in what they call “bureaucratic-politics-as-usual” 
times, the technical personnel of different kind, are more likely to play a prominent role (2). 
In the case of Malawi, the people who had taken part in the process were of different 
character. There were senior and relatively prominent people representing the Ministry of 
Health, and other less prominent people, also in the donor community. Whether or not they 
answered strictly to official policy issues, is difficult to judge as the policy documents are 
few. The time span since the actual discussions had taken place was said to be a challenge for 
all the respondents. This could make the recall of details in the process more difficult, and 
make the memories more selective. 
 
The role and the interaction of the participants in the process in this case study, was very 
much a result of the organization they represented at the time. In GAVI, the UN agencies are 
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no longer the leaders, and the donor countries and agencies hold the majority vote (20). 
However, it now has to cooperate with other stakeholders through GAVI. Many would argue, 
and particularly within WHO, that WHO is still the lead agency on vaccines and 
immunization at the global level. One could ask if the WHO influence is different in 
countries. The persons interviewed in Malawi referred to WHO as an important stakeholder in 
GAVI and together with UNICEF seen as the main actors in the ICC and one of the principal 
partners in GAVI. One in country partner representative said that WHO and UNICEF are the 
two agencies that run the decision making body that directs the Alliance, and that the 
information distributed by GAVI must be consistent and harmonized by WHO and UNICEF. 
The role of WHO in GAVI has not changed very much since the development of the Alliance, 
according to the interviews in this case study. On the other hand, there is literature concerning 
the complicated process of the creation of the Alliance, where the cooperation of WHO and 
UNICEF and the Alliance is described as somewhat difficult. In order to get GAVI off the 
ground, it was essential to bring WHO into the centre of the Alliance. WHO had been 
criticized for not being able to take the necessary steps, and take charge of the topic of 
immunization. WHO talks about being sidelined of vaccines in the 1990‟s, and did not feel 
the ownership in this area. This literature also talks of a continuous tension between the goals 
and operation of the GAVI and the interests of its principal partners. It says further that those 
who staff the GAVI infrastructure are constantly made aware of the ambivalence felt by both 
UNICEF and WHO toward the Alliance, and the ongoing danger of losing their interest and 
cooperation (2, page 243). None of the respondents expressed knowledge of any tension 
between any of the stakeholders during the decision making process. This might have been 
because there was none, or because they did not want to reveal this information. In a GAVI 
initiated evaluation, the constitution of GAVI with the diverse groups of organizations might 
possibly have been the biggest challenge to the initiatives in doing their work, because they 
are accountable to many interests (14).   One of the global partner representatives in this case 
study also talks about the criticism towards WHO and UNICEF for not taking responsibility 
when it came to new and underused vaccines, and said that little had happened in the 
vaccination area since the 1980‟s. He explains that the GAVI Alliance was created in order to 
achieve results quickly and efficiently. The point here is to underline the fact that the working 
of the Alliance is depending on the cooperation between its partners, and in trying to identify 
the political and institutional factors that affect the implementation of new and underused 
vaccines, WHO and UNICEF play a major role. It is reasonable to assume that the fact that 
the role of WHO and UNICEF has been subjects of discussion to this extend that is described 
Vaccine introduction at country level; a case study in Malawi 
 
Ellen Eie 69 
in the literature and in the interviews, especially in the early days of the Alliance, also 
influences the working of the Alliance, and the decisions made. According to Sandberg et al, 
there are at least two diverging positions in GAVI in whether to concentrate on new vaccine 
introduction or to concentrate on a wider set of objectives including strengthening health 
systems. In a global health perspective, the question being, should it prioritize basic services 
to everybody, or using new science and technology quickly? This study suggests that these 
diverging positions within the Alliance also affected the introduction of Hib vaccine globally. 
Initially, partners in GAVI united on a vision of securing equity in global immunization 
programmes through access to new technology. Equity could mean both an imperative to 
achieve fairer distribution of new health technologies globally, and a fairer distribution of 
overall health in a given country. Regime effectiveness studies have shown that the interplay 
between politics and knowledge can fuel the differences in underlying values which results in 
divergent positions in what an initiative seeks to accomplish. When there exists differences in 
interests, uncertainties might be more difficult to overcome, and might also fuel the already 
existing difference (4). 
 
International regimes very often come to an agreement that establishes specific rules, 
commitments and decision making procedures. The implementation will depend on each 
partners will and ability to adhere to the agreement (4). With the assumption that the board of 
GAVI is dominated by donors and Northern representatives as it is according to Hardon and 
Blume, the ownership of the agreement might be distributed differently among the 
stakeholders, and thereby maybe also the commitment to the agreements. 
 
5.2 A smooth transition 
 
Adding the two vaccines to the already existing immunization programme, was technically a 
smooth transition for the Malawi EPI due to the choice and approval of the pentavalent 
vaccine, the EPI being a “strong” vertical programme with dedicated personnel at the time of 
the introduction, and close communication with the WHO regional office. In discussing if 
global strategies to introduce new vaccines result in new practices at country level and “new 
practices at country level” is seen as if the existing immunization programme had to go 
through extensive changes in order to make the new vaccines “fit in” to the original EPI 
programme, the findings from this case study show that few new practices had to be 
introduced.  
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Most of the respondents‟ referred to the practicalities of the immunization programme when 
discussing whether or not the implementation of the new vaccines required changes in the 
existing immunization programme and with the approval of the pentavalent vaccine, only 
minor changes had to be done. This was also one of the reasons given for applying for the 
pentavalent vaccine, given by the country representatives, and the in country partner 
representatives; that the pentavalent vaccine would require minimal changes in the existing 
immunization programme.  
 
There had to be done some changes in their Information, Education and Communication 
(IEC) programme concerning the new vaccines introduced, the vaccine was delivered in a 
bigger vial, and a slight increase in the fluid given to the child, but the time for the injections 
remained the same, and it was still only one shot for the baby. If new practices at country 
level also include the financial side of the immunization programme, the answers are 
different. The remaining relatively high pries of the new vaccines, has caused new practices in 
the sense that the original financing system for vaccines is no longer sufficient for the new 
programme, and new discussions concerning priorities in the health sector has followed. 
 
One of the findings in this case study was that during the meetings concerning the 
introduction of the new vaccines, there was very little discussion going on. One of the 
hypothesis before going to the field, was that this topic would have caused a lot of discussion, 
as the cost of the vaccines are relatively high, the GDP per capita in Malawi is low, and the 
competing priorities in the Malawi health sector are many. Some of the respondents called it a 
smooth transition, others said there was little to disagree on. Malawi had for quite some time 
wanted the Hep B vaccine, but could not afford it, and when they learned of the GAVI 
Alliance, and the possible windows for support with the possibility of having the vaccines for 
free for five years, they applied, and the application was approved. It is important to notice 
here however, when later in the interview the question of financial sustainability came up, all 
the respondents answered extensively, and all of them said that the issues of future financing, 
what would happen after the five year support ended with the future pricing of the vaccines, 
where not brought up during the discussions before the application was sent to GAVI.  
 
There were still some challenges posted concerning the new immunization programme. In the 
Malawi Plan of action for 2000, and in their five year plan of action for 2001-2005, many of 
the same challenges are listed. This include amongst others establishing a budget line for the 
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procurement of the vaccines, soliciting funds to procure Hep B, soliciting long term continued 
external support, monitoring of routine immunization and identifying low coverage areas, the 
infrastructure concerning transport, funds and infrastructure for cold chain activities, shortage 
of EPI stationary, and under reporting of neonatal tetanus cases. As a general comment to the 
issue of new health interventions, Muraskin points out that a situation like this is aggravated 
by the fact that health workers have so many different jobs to do. Every new program comes 
along with great enthusiasm but then it crests and retreats (63). Again, many, and almost all of 
the respondents mentioned the financial aspect of the immunization programme as one of the 




The decision to introduce the new vaccines was not based on information on burden of 
disease or cost effective data. The information leading to the decision to introduce the 
vaccines was the information of the development of GAVI, and with it, a window where 
Malawi was eligible for support, and the information that there was a possibility to have the 
vaccines for free. 
 
In one of the concept papers for the SUM-MEDIC research project it is indicated that in the 
implementation of environmental agreements, implementation can be difficult due to the 
perceived relations between costs and benefits among implementation agencies. Costs are up 
front, concentrated and certain, while benefits are long-term, uncertain and diffuse (64). In the 
case of Malawi and the introduction of new vaccines, this situation is almost the opposite, 
where the long term cost is posed to be one of the biggest challenges for the future 
implementation. Although immunization can give long term benefits, the data showing the 
certainty of the effects of the vaccines are not available, due to lack of disease surveillance, 
and studies of efficacy and efficiency of the pentavalent vaccine in the Malawi population. In 
assessing the information flow during the decision making process, this case study aimed at 
tracing the content of the information important to the different stakeholders taking part. The 
information outlined as important for GAVI to receive from Malawi was that they knew of 
the eligibility criteria for support, and that they had the necessary information in order to 
complete their application for support from GAVI. The eligibility criteria were outlined, and 
the information concerning if Malawi met these criteria were easily obtained through official 
UN websites. One important criteria of information concerning the eligibility, is the 
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immunization coverage in the country. The official information on immunization coverage 
was available for GAVI before Malawi sent their application. Malawi answered to the criteria 
for support for the introduction of new vaccines, with reported immunization coverage above 
80%, but as mentioned in chapter 2.4.2 the information obtained concerning the immunization 
coverage numbers for and within the country varies. This challenge is also discussed in the 
study from Save the Children, where difficulties in obtaining valid and reliable immunization 
coverage data were seen as a challenge in both Tanzania and Mozambique (8). According to 
Hardon and Blume, the reliance on immunization coverage rates as performance indicators 
overlooks the absence of reliable health information systems in most countries applying for 
support, as well as problems in calculating coverage. Prior to this case study, the data on 
immunization coverage were obtained from the WHO, and the curiosity when developing the 
questions, was related to the information obtained by Malawi and the donor community that 
lead to the decision to introduce the new vaccines, rather than to how the immunization 
coverage numbers were obtained, and the reliability of the numbers. Taken into consideration 
the importance of the immunization coverage in getting support from GAVI, this could be a 
topic for further studies in Malawi, as the qualitative method and the objectives for this study 
do not cover this. 
 
One of the international norms on new vaccine introduction could be the information on 
disease burden. In the study from Thailand and Taiwan information on disease burden was 
found as a supporting factor in the introduction of new vaccines (2). This was also the case in 
the study from Qatar, Uruguay, Chile and Kuwait, where the key factor for the introduction of 
the Hib disease was the disease burden data and the severity of the disease (5). Mahoney 
suggests in the article concerning policy analysis that measurement of disease burden data and 
computation of vaccination cost effectiveness, are important elements of successful 
introduction of vaccines (6). Data on disease burden can raise the public concern, and could 
together with information on cost-effectiveness raise the level of information, leading to 
valuable knowledge on how the implementation of the new vaccines would require changes in 
the existing immunization programme in terms of future financing. Although some studies 
showed a relatively high prevalence of Hep B and Hib, one of the in country partner 
representatives emphasized that there were no data on disease burden in Malawi, only 
projections. In the application from Malawi to GAVI, there is given a budget summary for 
proposed activities where disease surveillance is given attention and where the need to 
quantify the burden of the problem of Hep B and Hib in Malawi is expressed (55). As stated 
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in the evaluation report by HLSP, unclear data on disease burden could mean a weak message 
on the desirability to incorporate the vaccine from WHO and a weak demand forecast as 
demand and need in countries with unclear disease burden could not be quantified. Without a 
clear disease burden the impact of the vaccine would be difficult to document, and therefore 
the countries could envision to drop the Hib vaccine once the support from GAVI ran out 
(14). This has already been outlined as an alternative by the Ministry of Health in Malawi. 
When the interviewees were asked if they found the information flow adequate during the 
decision making process, they all answered yes. Later in the interviews it became apparent 
that information concerning the issue of sustainability and what was going to happen after the 
five years of support was missing. With this knowledge in hand, one can ask if the 
information flow still can be considered adequate. Thus, the need for information seemed to 
change after the application was approved and the new vaccines were introduced, with the 
lack of information concerning the price of the vaccines and the issue of who is going to pay 
after the five years of support have finished, were areas where more information was needed 
according to all the stakeholders interviewed. The need for information on cost effectiveness 
and disease burden data was not expressed to the same extent. The issue for GAVI was to 
introduce vaccines quickly and effectively, and the issue of sustainability was not on the 
agenda then. It was important to change the picture that the issue of raising the immunization 
coverage in the poor parts of the world was not working very quickly. When the question 
came up of what would happen after the five years, the answer from GAVI was that this 
would be looked upon at a later stage; the important thing now was to get a quick scale up of 
the introduction and implementation of new and underused vaccines (i7.GPR). Regimes can 
affect actors differently because actors have different perspectives from which they judge 
costs and benefits and because the material consequences can differ. It was important for 
GAVI to achieve a quick scale up of the new vaccines. This was also important for Malawi, 
but more important the information on how the immunization programme should be sustained 
and how the changes in the material consequences for the existing immunization programme 





Vaccine introduction at country level; a case study in Malawi 
 
Ellen Eie 74 
5.4 The time frame and financial sustainability 
 
5.4.1 The time frame 
In trying to trace the actual decision making process, one of the findings of this study 
indicates that vaccine introduction processes do not start and end with country decisions to 
take the vaccine into the national immunization programs. They span over time, and decisions 
on global versus national financing may follow several years down the line, and with it, the 
discussion on whether to keep the Hep B and Hib vaccine in the existing immunization 
programme.  
 
The time frame for the decision making process is closely connected to the issue of financial 
sustainability, and these two findings might be hard to separate, although an effort will be 
done to do so in the following. The two chapters might overlap slightly in order to cover both 
topics. 
 
When time is mentioned in other studies as a challenge to the process, the relatively short 
time limit for the application process is discussed, and not so much the time frame for when 
the decision making process starts and ends, although it is possible to think that the short time 
for the writing and submission of the application also can influence the content of the 
discussion. If the stakeholders have the feeling of limited time during the discussion it might 
be possible that the most complex topics will not be discussed in depth, or that it might give 
less time to search for possible challenges and problems concerning the implementation in the 
future. In the study by Save the Children (Starling M. et al, 2002), all countries experienced 
pressure to make rapid decisions and were in some cases subject to what they call 
unreasonable tight deadlines in the application process. The study does also mention however, 
the risk of withdrawing the combination vaccines from the immunization programme due to 
the possible lack of funding, but suggests that this might be too politically sensitive to do for 
the governments. In addition to the susceptible risk of changes in the epidemiology in a 
population by withdrawing a vaccine which have been given for some years, the financial 
sustainability issue might also interrupt the basis for the agreement, or what was set at the 
outset as widely accepted principles and norms which should govern the implementation 
process, or the agreement, of new vaccine introduction, and thereby risking that the 
implementation of the new vaccines into the original immunization programme is no longer 
Vaccine introduction at country level; a case study in Malawi 
 
Ellen Eie 75 
successful. Regime studies looks at how cooperation works in practice, and changes in 
partners interactive decision making can be considered outcomes of regimes. As the five years 
of support was moving to an end in Malawi, the financial challenges became more apparent, 
and with it, the possibility of a political challenge where they move away from a situation 
where the actors share the same preferences, interests and values about an issue (4). A 
somewhat complicating issue in this situation is that although the decision making process is 
still going on; the countries have to keep the programme performing in order to get support.  
 
The assumption prior to this research was that the decision making process had already 
happened, and the process ended with the launching of the new vaccines into the new 
immunization programme. This was not the case for Malawi. The vaccines were incorporated 
into the immunization programme, but the health policy makers are still discussing how to 
keep them in the programme, mainly due to the financial sustainability issue, and as already 
mentioned, removing them from the programme was outlined as an alternative. This is an 
important finding for many reasons. Methodologically, this influenced both the content of the 
questions asked during the interview, and the approach of possible actors taking part in the 
process. With this knowledge now at hand, more, and other, actors could have been a part of 
the research, as the health policy makers working with immunization from the beginning of 
the discussions until today, would be of great interest. This would also have motivated a 
greater interest in the issue vaccine prices and financial sustainability at the outset of the 
research, both as a topic for discussion with the stakeholders, and for further discussions 
concerning possible solutions and financing mechanisms, and how the stakeholders perceive 
future introduction of new vaccines. Some of the actors already interviewed were a part of the 
immunization programme today however, but this was a coincidence in the research, not a 
result of a deliberate approach. 
 
GAVI has now recognized that their original policies regarding the introduction of new and 
under used vaccines was based on incomplete information and erroneous assumptions. Based 
on this experience, there is now a general consensus that countries must have an appreciation 
of the costs and financing of new vaccine introduction at the outset, not mid way through the 
process, as was the case in phase 1. Increased predictability of future expenditure on vaccines 
is important for countries and for manufacturers, to ensure adequate supply and affordability 
in the long term. This was hindered in phase 1 as the basic predictions GAVI used were 
unrealistic (63, page 263). According to Muraskin`s report, the implementation of new 
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vaccines should be integrated with, and subordinated to, broader systems objectives. As 
outlined earlier in this thesis, Malawi has many contending health issues on the agenda. 
Muraskin argue that the introduction of the vaccines should be determined by its effect on the 
overall mission of strengthening the entire health system, with the vaccine Alliance (and 
others) helping in keeping the focus on the importance of immunization. In order to achieve 
sustainable immunization programmes there should be built strong foundations that will 
support the lasting achievements (63). Hardon and Blume argue that GAVI run the risk of 
creating health inequities in the poorest countries, which they have prioritized for support. 
Seeing these arguments in perspective, Malawi has to have a continuous priority process, 
where the immunization programme is one of many contending programmes in Ministry of 
Health. The finding in this case study, therefore, that the decision making process is still 
going on, might not be so surprising. The introduction of SWAp can also have contributed to 
this situation, as the EPI programme is now integrated into the health sector as a whole, 
sharing the common resources, instead of being a vertical programme with its own funding 
mechanisms. One of the differences in the discussion now, is that the vaccines are already 
implemented.  
 
5.4.2 Financial sustainability 
An important and unexpected finding in this case study will be given attention in the 
following chapter. In trying to summarize it; there was little discussion concerning whether 
the new vaccines should be implemented in the immunization programme or not. The 
discussion came later when it became apparent that GAVI funding would cease after five 
years and the price of the vaccines had not dropped. The discussion about the new vaccines is 
tied to financial sustainability and the uncertainty about prices. 
 
Interestingly, Malawi Ministry of Health, do not see financial sustainability as being self-
sufficient, but as the ability for the donors to finance the programme in the future. The 
immunization programme in Malawi is heavily donor dependent. This case study suggests 
that the sustainability of the immunization programme depended on if the donors would be 
available to provide funds for procurement of the vaccines (i1.ICPR).   
 
Prior to GAVI and the introduction of the new vaccines, the Malawi Government already had 
a future policy and work plan for their immunization programme, referred to as the five year 
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plan, or the Malawi Multi Year Plan, and therefore only needed to revise this when the 
request came from GAVI for a Multi Year Plan. The plan was attached to the application sent 
to GAVI in 2000, together with the statement that the EPI Unit planned to produce a 5 year 
Plan of Action later in the same year. However, at the time of the introduction, Malawi was 
not really prepared to fund the vaccine that would cost them around 5 dollars, with the total 
health expenditure per capita being 10 dollars (i2.CR). The stakeholders involved in the 
discussions concerning the introduction of new vaccines to Malawi, were aware of GAVI‟s 
plan for support for five years. The challenge was that there was no clear plan for what was 
going to happen after the five years, and this was not brought up as a topic for discussion 
during the decision making process. The Malawi Government sought advice, and the advice 
they received from WHO was to go for the new pentavalent vaccine, as they all believed the 
prices of the vaccines would be reduced and therefore more affordable for the countries after 
the five year period. The price of the vaccines did not drop as expected, and the issue of what 
was going to happen came up almost half way into the five year period of support in Malawi‟s 
case, with the request from GAVI for a financial sustainability plan. This request is seen as 
the starting point for the discussions concerning the financing issues, and the time when 
Malawi became aware of the price of the new vaccines.  The new pentavalent vaccine was 
already introduced, and it was expensive. It is reasonable to assume, that Malawi‟s possibility 
to influence on vaccine prices is very low, and with the high donor dependency, the 
government‟s influence on future finances is at least limited. The power and the capacity to 
meet the challenge of financial sustainability of the immunization programme, could then be 
limited to the alternative of withdrawing the pentavalent vaccine from their immunization 
programme.  
 
From GAVI‟s point of view it was important to introduce the idea of the vaccines actually 
having a price, therefore the financial sustainability plan, and thereby encourage the countries 
to give something. The introduction of the financial sustainability plan was interim measures 
to begin accustom the countries to the idea that the price shock at the end of phase 1 might not 
be quite as light as it was thought to be. The concept of financial sustainability and what could 
increase the countries possibilities of being able to sustain their own immunization 
programme is complex. An argument for what makes the long term commitment a challenge 
is given by Muraskin; “Provision of five years worth of vaccine free and subsequently 
expecting 100% transition to national government and partners is impractical…even if a given 
vaccine is not a national priority, an offer of free vaccine for five years is difficult to refuse, 
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therefore initial country uptake is not an accurate measure of long term commitment” (63, 
page 263). It is believed, that the responsibility concerning the question of what is going to 
happen after the five years should be shared by all the stakeholders who took part in the 
process. WHO gave advice to go for the pentavalent vaccine, and strongly believed that the 
prices was going to decline, Malawi had been waiting for a financial opportunity to introduce 
the Hep B vaccine, and took the advice. The issue of financial sustainability was not raised to 
any extent during the decision making process by any of the stakeholders. One reason could 
be lack of ownership to the programme with the new vaccines provided for free. 
 
The study from Save the Children showed that the lack of consensus in terms of future 
financing beyond the five year time frame was stark. It is argued that for Ministries of Health, 
for so long being dependent on external support, remain pragmatic in anticipating that funds 
will eventually follow the plans and priorities of the sector, and as time frames for donor 
commitments usually is one or two years, a five year commitment is welcomed. Consistent 
with the findings from the case study in Malawi, the lack of discussion and co-ordination 
around future financing, involving the major donors at the country level, was a notable 
finding (8). Gauri and Khalegian argue that donor presence at country level tends to 
strengthen EPI, but slow the adoption of new vaccines (9). Unfortunately, neither the persons 
from DFID or NORAD, or other major donors to the health sector of Malawi who was 
involved in the discussions at the time, were able to take part in this case study, and therefore 
no conclusions can be drawn from a donor perspective on the future financing of the new 
immunization programme in Malawi.  
 
In Munira and Fritzen`s article it is emphasized that a challenge in a large number of countries 
in the developing world is the power and resource asymmetries between donors bringing 
much needed finance on the one hand, and the country health and finance ministries on the 
other (2). As we have seen from the regime studies, the configuration of power may influence 
the behavior and effectiveness of international commitments, and more so when the actors no 
longer share the same interests and values about an issue (3, 4). An effect of continued 
relatively high prices of vaccines could result in the continued discussions and uncertainties 
of the ability for Malawi to sustain the new vaccines in their immunization programme, and 
with it, reduce the effectiveness of the agreement from 2000 to do so. The explanations for the 
persistent relatively high prices of the vaccines were mainly the marked forces not yet having 
had the necessary effect on price reduction, with too few manufacturers of the pentavalent 
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vaccine in the marked. It was also mentioned that UNICEF played a role in negotiating price 
reduction, and did not manage to do this sufficiently. In a regime implementation perspective, 
the global enabling environment, which in this case could be the marked forces or price 
negotiations, and which should act as a positive force in order to make the implementation of 
new vaccines effective and successful, is reduced. The agreement and commitments set at the 
start of the implementation of the new vaccines in the original EPI programme in Malawi, 
might have been perceived differently from the different stakeholders taking part in the 
decision making process, without the stakeholders being aware of the mismatch in the 
understanding of the agreement. Another explanation could be that the knowledge of the 
mismatch was present, but together with the expectations that these challenges will be solved 
during the years to come, before the support from GAVI ended, all the stakeholders agreed on 
the fact that the continued high prices of the vaccines became a somewhat unexpected 
challenge towards the end of GAVI phase 1. Whatever the reason, one of the effects of the 
high price of the vaccine is continued discussions around the original agreement to introduce 
the vaccines, and this might also possibly affect the international cooperation concerning new 
vaccines. Increased tension and disagreement among the stakeholders concerned with 
immunization, and the coordination of action concerning the international commitment to 
combat infectious diseases might become less effective, but the result can also be more 
discussions, increased knowledge, and thereby increased awareness concerning this global 
challenge. If the latter becomes the case, the agreements on solutions, and the implementation 
of the actions might have a better chance of success. In the article concerning the policy 
analysis for the introduction of vaccines in developing countries, the creation and sustenance 
of funding mechanisms for procurement of the vaccine is said to be one essential element for 
successful introduction (6). This is consistent with the study from Malawi from 1997, prior to 
GAVI, where the over dependency on donors and the financial uncertainty is already 
expressed as a factor that may disrupt the existing supply system for vaccines (30). 
 
It has also been argued by Hardon and Blume that donor dependency for the procurement of 
the vaccines is being reinforced under GAVI. GAVI was able to generate resources for wide 
scale introduction of the new, more expensive combination vaccines, and have in a relatively 
short time developed mechanisms to process and approve developing countries requests for 
support to obtain the new vaccines. However, they also express concern for the sustainability 
of the current GAVI supported immunization programmes in developing countries, and the 
possibilities for an increase in the disparities in access to vaccines, as the countries might be 
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unable to sustain the supply of new and improved vaccines if the global resources flow 
diminishes. GAVI has been addressing the sustainability and equity issues however, and 
although they are „learning by doing‟ and making mistakes, the Alliance is proving to be a 
dynamic coalition (20).  
 
The issue of future financing of the immunization programme was, and still is, an increasing 
concern for all the stakeholders involved in the process. Of the political and institutional 
factors that affect the implementation of new vaccines in Malawi, financial sustainability and 
vaccine prices are two of the most important ones. Had the five year period been absolute, the 
capacity for Malawi and the stakeholders in immunization for problem solving would have 
been very limited. This is not the case however, as GAVI is extending their support, and the 
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6 Conclusion 
 
The findings from this case study were not as expected. One hypothesis was that there would 
have been extensive discussions concerning the introduction of the new vaccines at the time 
the decision was taken. This was not the case. At the same time the fact that the issue is still 
being discussed was an unexpected finding. With the knowledge obtained through interviews 
and documents, this research suggests that from the technical perspective, the introduction of 
the new vaccines went smoothly. Looking at it from a public health perspective, there are 
underlying challenges concerning the immunization programme and the Malawi health 
system that have prevailed since before GAVI. Seen from a political and financial 
perspective, the decision making process around the introduction of the new vaccine is 
complicated and ridden by high uncertainties. The questions one can ask is what 
responsibility the Malawi Government has to continue their commitment to increase and 
sustain immunization coverage, and to what extent can private foundations which provide a 
large proportion of funds for such efforts, be held accountable. 
 
The performance based support encouraged by GAVI and the reliance on immunization 
coverage rates as performance indicators might be based on at least varying, and maybe also 
the wrong assumptions. The health information systems in many countries applying for 
support from GAVI might not be reliable. In the case of Malawi, this is not fully explored, 
and no conclusion can be drawn about the immunization coverage numbers given, but-given 
the variety in numbers obtained in this case study, it might at least be questioned. The health 
information system and how the immunization coverage numbers are obtained might be a 
topic for further studies in Malawi, together with possible prospect study on the new 
financing mechanisms of GAVI, how it will work, and who ends up paying the bill if the 
prices still do not decline as expected, together with other new vaccines waiting for 
implementation. This would probably demand for quantitative research as well as qualitative. 
 
In order to lift focus, and see the global and international enabling environment concerning 
the introduction of new vaccines in Malawi, the analytical framework became a useful 
guidance in understanding and analyzing the results of this study, and in giving an important 
perspective to the subjects which evolved. However, the concept of applying the framework 
of regime studies , is still quite new, and few other studies where this is applied in analyzing 
the implementation process of vaccines are available for comparison. 
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Due to limited data, it can be difficult to draw any conclusions on whether global strategies to 
introduce new vaccines results in new practices at country level or whether implementation of 
the new vaccine requires changes in the existing immunization programme. Nevertheless, 
issues evolved which could suggest useful directions for further research concerning 
international agreements in global health, and for the further implementation of the vaccines 
in Malawi‟s immunization programme. One lesson learned is that the decision making 
process to not end with the as the new vaccine is included in the immunization programme, 
and this should be taken into consideration in future studies as this will have effect on who 
and how the topic is approached. The practical introduction of the pentavalent vaccine went 
smoothly and the introduction of SWAp had a somewhat greater influence on the policy 
context than did the introduction of the new vaccines the effect of its existence will not be 
seen to the full extent yet. This study has also given an indication of the importance of further 
studies on burden of disease and cost effectiveness. The topics vaccine prices and financial 
sustainability were not a part of the objectives at the outset of this thesis, and were also new 
and unexpected findings in this study. Although not entirely new, it is the impression that 
these findings can give useful information for further studies concerning the same topic, in 
Malawi or other countries for comparison. One lesson could be to extend the time frame for 
the process, and thereby include more stakeholders including persons in Ministry of Finance 
and the donor community, as the financial aspect of immunization seems to be of great 
importance. With the cost of the vaccine now becoming a big issue, the focus on the disease 
burden has increased. As GAVI is now entering its phase 2, where vaccines are no longer 
given for free and the issue of co financing has been established, it could be interesting to see 
if this has an effect on the perception of the importance of the information on disease burden 
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